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ABSTRACT OF DISSERTATION 
 
 
ROLE OF OXIDIZED EXTRACELLULAR VESICLES AS EARLY BIOMARKERS 
AND INFLAMMATORY MEDIATORS IN CHEMOTHERAPY-INDUCED 
NORMAL TISSUE INJURY 
 Significant advances in the efficacy of cancer therapy have been 
accompanied by an escalation of side effects that result from therapy-induced 
injury to normal tissues. Patients with high grade cancer or metastasis are often 
treated with chemotherapy, 50% of which are associated with reactive oxygen 
species generation and cellular oxidative stress. Heart is the normal tissue most 
susceptible to chemotherapy-induced oxidative stress and heart disease is the 
most common leading cause of death in cancer survivors. However, early and 
sensitive biomarkers to identify heart disease are still lacking. Extracellular 
vesicles (EVs) are released from cells during oxidative stress and send oxidized 
proteins into the circulation as a compensatory mechanism that prevents cellular 
proteotoxicity. Thus, the protein contents of EVs released during the pre-
degeneration stage reveal that oxidative stress is occurring early in the damaged 
tissue. Using a mouse model of doxorubicin (DOX)-induced cardiac injury, we 
demonstrated that EVs can be used as an early diagnostic tool for tissue injury 
as they are oxidatively modified with 4-hydroxynonenal and contain tissue 
specific proteins—glycogen phosphorylase brain/heart, muscle, and liver 
isoforms—that indicate their origins. These biomarkers increased early, before 
the changes of conventional biomarkers occurred.  
EVs also mediate intercellular communication by transferring bioactive 
molecules between cells. In the cell culture system, EVs play an important role in 
oxidative stress response by inducing macrophage polarization. EVs from 
cardiomyocytes promoted both proinflammatory (M1) and anti-inflammatory (M2) 
macrophage polarization evidenced by higher pro- and anti-inflammatory 
cytokines and nitric oxide generation, as well as mitochondrial oxidative 
phosphorylation suppression and glycolysis enhancement. In contrast, EVs from 
the hepatocytes supported anti-inflammatory macrophage (M2) by enhancing 
oxidative phosphorylation and anti-oxidant proteins. DOX promoted the 
immunostimulatory effects of cardiomyocyte EVs but not hepatocyte EVs. The 
differential functions of EVs on macrophage phenotype switching are due to their 
 
 
different effects on Thioredoxin 1 redox state, which regulates activities of redox 
sensitive transcription factors NFκB and Nrf-2. Our findings shed light on the role 
of EVs as a redox active mediator of immune response during chemotherapy. 
KEYWORDS: Doxorubicin, extracellular vesicles, biomarkers, oxidative stress, 
macrophage polarization 
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CHAPTER 1. INTRODUCTION 
Improved cancer treatment has raised the five-year survival rate of adult 
cancer patients from 49% in the late 1970s to 69% between 2005 and 2011. In 
childhood cancer patients, the survival rate is even better, having improved from 
58% in the 1970s to 83% by 2011. However, these gains have been 
accompanied by increased risks. The longer a cancer patient lives, the greater 
the possibility that complications from cancer treatment will occur. Complications 
can arise, in part, from oxidative stress-induced damage to noncancerous tissue, 
which decreases the quality of life of cancer survivors. Treatment-related side 
effects such as cardiotoxicity are the third leading cause of death in adult and 
childhood cancer survivors. Recurrence and secondary tumors are the first and 
second leading causes of death, respectively [1]. The American Cancer Society 
has predicted that there will be 20.3 million long-term cancer survivors in the U.S. 
by 2026. This immense number of survivors will necessitate an emphasis on 
preventive strategies that preserve normal tissues while killing cancer cells. 
Currently, 215 drugs have been approved by the FDA to treat cancer. At 
least fifty percent of them can induce oxidative stress, among them Doxorubicin 
(DOX) is the best-known cause of late-onset cardiomyopathy in cancer patients. 
Oxidative stress is a well-accepted mechanism of DOX-induced cardiotoxicity. 
Excessive reactive oxygen species (ROS)/ reactive nitrogen species (RNS) that 
reaches the threshold of antioxidant capacity of the cells, as well as the 
accumulation of oxidized biomolecules that overwhelm the biomolecular quality 
controls of cells, cause cytotoxicity to cancer and normal cells. To combat 
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against oxidative stress-induced cytotoxicity, the cells have evolved several 
pathways to remove oxidized toxic molecules including proteasome-mediated 
degradation and autophagy, as well as removing the toxic molecules in the form 
of extracellular vesicles.  
Extracellular vesicles (EVs) are membranous encapsulated structures that 
are released from almost all cell types. EVs are heterogeneous in size, contents 
and biogenesis. They are generally classified into 3 types based on the 
biogenesis: exosomes, microvesicles, and apoptotic bodies. EVs serve as a 
compensatory mechanism to remove oxidized molecules under oxidative stress 
condition to maintain cellular homeostasis. The oxidized molecules of EVs are 
stable in the environment due to protective lipid bilayer making them potential 
biomarkers for oxidative stress-related diseases including DOX-induced 
cardiotoxicity. 
EVs also serve as a vehicle that transfers bioactive molecules between 
cells, thus mediating cell-cell communication during cellular stress. Innate 
immune response plays a crucial role in the progression of heart failure. 
However, how cardiomyocytes communicate with immune cells during DOX-
induced cardiotoxicity is still unclear. The overall goal of this study is to 
investigate the role of EVs as biomarkers and mediators of chronic inflammation 
in DOX-induced cardiomyopathy. Understanding of cellular communication 
during chronic inflammatory processes in DOX-induced cardiomyopathy will help 
develop new therapeutic approaches for treatment and prevention of this 
disease. 
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Doxorubicin-Induced Cardiomyopathy 
DOX is one of the most effective anticancer treatments that has a broad 
range of therapeutic activities against both hematological and solid tumors, 
including breast cancer, ovarian cancer, soft-tissue and bone sarcoma, non-
Hodgkin’s and Hodgkin’s lymphoma, and multiple myeloma [2]. However, DOX 
carries a severe chronic side effect known as doxorubicin-induced 
cardiomyopathy, which eventually leads to heart failure. The risk of heart failure 
development increases rapidly when the patients receive a cumulative dose of 
DOX > 550 mg/m2 [3]. Evidence of heart failure can present years after cessation 
of the treatment [4]. Doxorubicin-induced cardiomyopathy has a poor prognosis 
with the mortality rate as high as 61% [5]. Pathologic finding from myocardial 
biopsy from patients with doxorubicin-induced cardiomyopathy is characterized 
by loss of myofibrils and cytoplasmic vacuolization [4]. The risk to develop DOX-
induced cardiomyopathy is difficult to identify because individual sensitivity to 
DOX is diverse and there is no ideal monitoring test to predict late onset 
cardiomyopathy. Most of the biomarkers used in the screening for cardiovascular 
disease development such as cardiac troponin T and B-type natriuretic peptide 
can be detected after cardiac injury and neurohormonal changes [6], which may 
occur too late to begin the treatment. To prevent cardiac outcome promptly, 
identification of individual risk and early diagnosis by sensitive non-invasive 
biomarkers are needed. 
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Mechanisms of Doxorubicin-Induced Cardiomyopathy  
Decades-long research has explored the mechanisms by which DOX 
causes cardiomyopathy via multiple pathways [5]. DOX-induced cardiomyopathy 
engages not only cell death related signaling pathway in cardiomyocyte itself but 
also the intercellular communication leading to tissue inflammation and 
maladaptive remodeling.  
The generation of ROS and RNS is an initial event of DOX-induced 
cardiac tissue injury. Mitochondria are the major subcellular organelles affected 
by DOX since DOX has 300-1000 fold higher affinity for binding to cardiolipin, a 
major component of inner mitochondrial membrane, compared to other anionic 
phospholipids [7]. The redox cycling of quinone-DOX to the semiquinone radical 
formed by diverting one electron from NADH dehydrogenase at complex I and 
donating the electron to molecular oxygen gives rise to superoxide radical (O2•-) 
formation [8]. O2•- can also be generated by other enzymatic reactions such as 
cytochrome P450 reductase, xanthine oxidase, and uncoupled nitric oxide 
synthase, as well as non-enzymatic reactions from redox cycling of DOX-Fe3+ 
complex [9]. 
Manganese superoxide dismutase (MnSOD) is the major enzyme 
responsible for mitochondrial O2•- removal, yielding hydrogen peroxide (H2O2) as 
a product. H2O2 can be further detoxified by catalase and glutathione peroxidase. 
However, excessive superoxide radicals can react with other ROS and RNS such 
as H2O2 and nitric oxide radical (NO) to form more highly reactive ROS/RNS. 
 
 
5 
Aconitase is a tricarboxylic acid cycle enzyme responsible for catalyzing 
the conversion of aconitate to isocitrate [10]. Aconitase contains iron-sulfur 
clusters that are sensitive to O2•- inactivation, which results in the release of Fe2+ 
from the enzyme [11]. O2•- can also induce the release of Fe2+ from ferritin, an 
intracellular iron storage protein [12]. Fe2+ further catalyzes the interaction of O2•- 
with H2O2 leading to hydroxyl radical (OH) generation. The interaction of O2•- 
with NO generates peroxinitrite (ONOO-). Both ONOO- and OH are highly 
reactive and can damage biomolecules such as lipids, proteins and nucleic acids. 
Unsaturated fatty acids, major components of the cellular membrane, 
contain carbon-carbon double bonds making them susceptible to ROS/RNS 
attack. Two major ⍵6 lipid peroxidation products derived from nonenzymatic 
ROS/RNS attack are malondialdehyde (MDA) and 4-hydroxynonenal (4HNE). 
Among the major lipid peroxidation products, 4HNE is the most toxic. 4HNE 
rapidly reacts with thiols and the amino groups of amino acids leading to 4HNE 
protein adduction. It has been shown that protein-bound 4HNE forms early after 
DOX treatment. In cardiac mitochondria, protein-bound 4HNE forms as early as 3 
hours following treatment and rises to its highest level at 6 hours post- treatment. 
An increase in 4HNE-bound proteins occurs in mitochondria prior to occurring in 
cytoplasm and nucleus [13]. A high level of 4HNE leads to inactivation of the 
adducted proteins. Our recent study showed that during DOX treatment, 4HNE-
adducted proteins in heart tissues that are involved in the electron transport 
chain, such as succinate dehydrogenase A (SDHA), dihydrolipoamide 
dehydrogenase (DLD), ATP synthase subunit β (ATP5B), and NADH 
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dehydrogenase [ubiquinone] iron-sulfur protein 2 (NDUFS2), led to mitochondrial 
respiratory dysfunction and a shift of energy production to glycolysis [14]. 
Furthermore, 4HNE adduction to mitochondrial protein, as in mitochondrial 
apoptotic inducing factor 2 (AIFM2), can alter the protein function from 
oxidoreductase to pro-apoptotic protein leading to cardiomyocyte cell death [15]. 
Cellular Mechanisms to Maintain Homeostasis against Oxidative Stress  
Cells contain several protein quality control (PQC) mechanisms that 
maintain physiological homeostasis against highly toxic oxidized protein 
accumulation. Those mechanisms involve protein unfolding via endoplasmic 
reticulum, intracellular protein degradation via the ubiquitin-proteasome pathway, 
autophagy-lysosomal pathways, and extracellular vesicles release [16-18]. PQC 
is highly regulated by the cellular redox status. A growing body of evidence 
shows that DOX affects PQC in cardiomyocytes leading to the accumulation of 
oxidized proteins and eventually cell death [18,19]. 
Protein Unfolding System 
Protein oxidative modification involves a disturbance of protein folding 
resulting in aberrant protein conformations that affect protein function, stability 
and solubility [20]. Protein unfolding occurs in the organelle Endoplasmic 
Reticulum (ER) where it serves as a first- line response against toxic oxidized 
proteins. Protein unfolding is initiated by stress-sensor proteins on the ER 
membrane, activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 
(IRE1), and protein kinase RNA-like ER kinase (PERK). ATF6 and IRE1 
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activation initiates an adaptive response by upregulating 78 kDa glucose-related 
protein (GRP78), an ER chaperone protein responsible for regulating protein 
folding. PERK activation regulates negative feedback control by inhibiting protein 
translation and thus alleviating ER workload [21]. However, excessive ER stress 
initiates the apoptotic pathway mediated by caspase-12, c-Jun NH2-terminal 
kinase (JNK) and C/EBP homologous protein (CHOP). A histological study of 
endomyocardial biopsies from patients experiencing DOX-induced cardiotoxicity 
revealed extensive ER dilation [22], suggesting that ER stress is a major 
mechanism of DOX-induced cardiotoxicity. Recently, a study in mice revealed 
that DOX activated ATF6 and IRE1 but failed to upregulate GRP78 gene 
expression leading to a shift from ER adaptive stress response to the apoptosis 
response [23]. 
Ubiquitin-Proteasome System (UPS) 
The Ubiquitin-proteasome system (UPS) is responsible for removing 
cytosolic oxidized proteins, which are ubiquitinated by three classes of enzymes 
working in concert. Ubiquitin activation enzyme (E1) activates and transfers 
ubiquitin to ubiquitin conjugation enzyme (E2). Ubiquitin ligase (E3) positions the 
target substrate in order to transfer ubiquitin from E2 to lysine residues of the 
substrate. The polyubiquitinated proteins at lysines are subsequently recognized 
and degraded by the 26S proteasome. Alternately, oxidized protein without 
ubiquitination can be degraded by the 20S proteasome. UPS is highly regulated 
by the cellular redox status. Mild oxidative stress upregulates the ubiquitination 
machinery and proteasome activity. However, severe oxidative stress inhibits 
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proteasome activity yet it spares the ubiquitination systems. This leads to the 
accumulation of oxidized-polyubiquitinated proteins [24]. DOX is known to cause 
massive protein oxidation and ubiquitination. However, the role of DOX in UPS 
remains controversial. A study of H9c2 cardiomyoblasts treated with 3 µM DOX 
for 24 hours and tumor bearing mice treated with a cumulative dose of DOX at 20 
mg/kg revealed that DOX inhibits proteasome activity while it stimulates protein 
ubiquitination by increasing E3 ligase expression [25]. However, another study 
using a lower concentration of the therapeutic dose (0.1-5 µM) found that DOX 
upregulates E3 ligase, the C-terminal of heat shock protein cognate 70-
interacting protein (CHIP), and heat shock protein 70, as well as activates the 
20S proteasome [26]. Nevertheless, proteasome function relies heavily on 
protein unfolding for the translocation of the protein into the proteasome lumen to 
occur [27]. DOX levels that causes extensive oxidized protein misfolding and 
aggregration might compromise the UPS system despite the enhanced 
proteasome activity.  
Autophagy  
Autophagy, literally self-digestion, contributes to degradation of cytosolic 
protein aggregates and dysfunctional organelles. Damaged components of 
autophagy are trafficked to lysosome for degradation. This process can be 
mediated by three different pathways; macroautophagy, microautophagy, and 
chaperone-mediated autophagy (CMA). Macroautophagy is characterized by 
sequestration of the cargoes by double-membrane structures, which progress to 
autophagosome formation and subsequently fusion to lysosome for degradation. 
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The process of macroautophagy initiates with the activation of the unc-51-like 
autophagy activating kinase 1 (ULK-1) complex, which further activates Beclin-1 
and the vesicle-mediated vacuolar protein sorting (VPS34) complex—the two 
proteins that mediate phagophore formation. Subsequently, autophagy- related 
gene (ATG) proteins 5, 12, and 16 are recruited to the phagophore membrane 
and extend the phagophore. The cytosolic form of microtubule-associated protein 
1A/1B-light chain 3 (LC3-I) is then lipidated with phosphatidylethanolamine to 
form LC3-II, which is also recruited to the phagophore membrane. The 
ubiquitinated damaged protein substrate, along with p62/SQSTM1, interacts with 
LC3-II, all of which are then engulfed by phagophore to form an autophagosome. 
The final process is the fusion of autophagosome with lysosome and the 
degradation of autophagosome cargoes by lysosomal enzymes. Microautophagy 
directly engulfs the cytosolic component by invagination of lysosomal membrane. 
CMA requires heat shock-cognate protein of 70 KDa (HSC70) to recognize 
proteins that contain the pentapeptide sequence KFERQ. HSC70- bound 
KFERQ-containing protein then binds to lysosome-associated membrane protein 
type 2A (LAMP-2A) on the lysosomal membrane, which translocates the target 
protein into lysosomal lumen for degradation [28]. Blocking autophagic flux leads 
to an accumulation of oxidized proteins and organelles that are toxic to the cells. 
DOX has been shown to disrupt macroautophagy and CMA. The process 
of autophagy dysregulation following DOX exposure has been extensively 
reviewed [18,29,30]. DOX promotes autophagosome formation by increasing the 
LC3-II level and ATGs protein expression [31]. The DOX-derived lipid 
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peroxidation product 4HNE is also a potent activator of aldehyde-induced 
autophagy [32]. Our previous study found that p53 is a key player that drives 
JNK1-mediated autophagosome formation and p53 knockout mice are protected 
from DOX-induced oxidative stress in mitochondria [33]. Recently, Bartlett and 
colleagues reported that DOX inhibits vacuolar ATPase (VATPase), a proton 
pump on the lysosomal membrane that maintains the acidic pH required for 
lysosomal degradation. Furthermore, the same group also found that DOX 
suppresses the expression of transcription factor EB, which is a key protein 
governing lysosomal content and function [34]. These lysosome- blocking effects 
lead to an accumulation of undegraded autolysosomes resulting in additional 
ROS production and cardiac injury [35].  
Mitophagy 
Healthy mitochondria are required for ATP generation that supports 
cardiac contractility. Mitophagy, which has a major influence on the quality of 
mitochondria, relies on autophagy machinery. Two mitophagy pathways have 
been described in cardiomyocytes— (1) the Phosphatase and tensin homolog-
induced putative kinase 1 (PINK1)/ E3 ubiquitin-protein ligase Parkin-mediated, 
and (2) the BCL2 interacting protein 3-like (Bnip3L)/Nip3-like protein X (NIX)-
mediated pathways. The PINK1/Parkin pathway is triggered by mitochondrial 
membrane depolarization, which promotes the stability of PINK1, a 
serine/threonine kinase located on the mitochondrial outer membrane. PINK1 
then attracts and binds to Parkin, which subsequently ubiquitinates proteins 
responsible for mitochondrial movement cessation and mitochondrial 
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fragmentation maintenance. This ubiquitination process targets the damaged 
mitochondria for lysosome degradation [36]. In contrast to the PINK1/Parkin 
pathway, the Bnip3L/NIX pathway does not require mitochondrial membrane 
depolarization but involves phosphorylation near the LIR motif of Bnip3L, which 
makes it a docking site for LC3-II on autophagosomal membrane.  
DOX affects PINK1/Parkin and Bnip3L/NIX mitophagy in different ways. 
DOX suppresses PINK1/Parkin mitophagy by reducing PINK1 mitochondrial 
translocation. Hoshino and colleagues reported that DOX-induced p53 activation 
leads to the interaction and sequestration of PINK-1 by p53 [37]. In contrast, 
DOX enhances Bnip3L/NIX mitophagy by inducing mitochondrial translocation of 
Bnip3L, which leads to mitochondrial depolarization and Parkin recruitment [38]. 
However, cytosolic sequestration of PINK1, the Parkin partner, may blunt the 
effect of the Bnip3L pathway. Although DOX can either suppress or activate the 
upstream process of mitophagy, lysosome dysfunction caused by DOX, which 
blocks the end process of mitophagy, could lead to the retention of undigested 
damaged mitochondria. 
Extracellular Vesicles 
“Extracellular vesicles” is a general term that applies to membranous 
vesicles released from cells into extracellular space. EVs are composed of a lipid 
bilayer that encapsulates a variety of biomolecules, including proteins, DNAs, 
RNAs, and carbohydrates, as well as subcellular organelles such as 
mitochondria [39,40]. EV cargoes are resistant to enzymatic degradation owing 
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to the lipid bilayer shelter. EV stability has been evaluated in various conditions. 
Serum EVs are stable up to 24 hours at room temperature, 1 week at 4 °C, and 
fewer than 3 freeze-thaw cycles. Prolonged storage beyond the indicated time 
period and too many freeze-thaw cycles will cause EV rupture and content 
leakage [41]. Milk-derived EVs can withstand acidic pH (pH = 2.0), a short boiling 
temperature (105 °C, 15 minutes), and snap freezing in liquid nitrogen. However, 
the same conditions significantly degrade cell-derived EVs by 90%, 90% and 
70%, respectively [42].  
Despite EV stability ex vivo, the half-life of EVs in vivo is only 2 minutes 
due to a rapid clearance by interaction with other recipient cells [43]. The ability 
of EVs released from one cell to interact with other cells makes EVs a mediator 
of cell-cell communication. EVs express docking proteins on their surface that 
could be recognized by the recipient cells. The message from one cell to the 
other could be achieved by interaction of EVs with cognate receptors on recipient 
cell surface, fusion of EV membrane with recipient plasma membrane, or 
phagocytosis and delivery of EV contents into the recipient cytosol [44]. 
EVs are heterogeneous in size, content and biogenesis. Exosomes are 
the smallest EVs (50-100 nm) and originate from invagination of late endosomal 
membranes forming multiple intraluminal vesicles (ILVs) called multivesicular 
bodies (MVB). Those ILVs become exosomes when they are released by the 
fusion of MVB membrane with plasma membrane. Microvesicles (200-1000 nm) 
are formed by outward budding of plasma membranes. Apoptotic bodies (>1000 
nm) are generated by apoptotic cell fragmentation [45].  
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Exosome Biogenesis 
MVB formation requires machinery that not only sorts proteins to the 
endosomal membrane but also sorts proteins involved in changing membrane 
curvature and vesicle scission. Endosomal sorting complexes required for 
transports (ESCRTs: ESCRT-0 to ESCRT-III) are the best-known protein 
complexes that govern protein loading into exosomes. ESCRT-0 binds to 
ubiquitinated protein cargo and distributes it to MVB membranes. ESCRT-I 
associates with ESCRT-0 and ubiquitinated proteins to assist with the membrane 
translocation. ESCRT-II is a bridge that connects ESCRT-I to ESCRT-III, which is 
key to membrane budding and vesicle formation. In the final step, vacuolar 
protein sorting-associated protein 4 (VPS4) complex dissociates ESCRT-III 
thereby recyling the ESCRT machineries [46]. However, ESCRT is dispensable 
to MVB generation in some cell types. For example, oligodendroglial cells utilize 
neutral sphingomyelinase to generate ceramide forming lipid-raft microdomain for 
endosomal membrane budding [47]. In lung cancer cell lines after radiation, p53 
is activated leading to transcription of tumor suppressor activated pathway-6 
(TSAP6), a transmembrane protein involved in MVB formation [48,49]. The p53-
dependent MVB formation explains how DNA damage promotes exosome 
release. 
Protein sorting into MVB can be alternatively mediated by HSC70, a key 
protein that binds to oxidized protein in CMA. However, the interactions of 
HSC70 with the endosomal membrane and the lysosomal membrane are 
different. HSC70 relies on the electrostatic force from its basic residues to attach 
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to acidic phospholipids on the cytosolic part of endosomal membrane rather than 
binding to LAMP2A [28].  
Exosome biogenesis and autophagy are closely related. MVB cargoes are 
at a crossroads that could be sorted for degradation by lysosome fusion, or be 
released by plasma membrane fusion. The final destination of MVB is governed 
by the Rab family of small GTPases. Rab7 directs MVB to fuse with lysosomes, 
while Rab27A directs it to fuse with plasma membrane [50,51]. Thus, if one 
pathway is blocked, the cargo will pass to the other pathway. For example, 
ESCRT depletion in Caenorhabditis elegans enhances autophagic flux, which 
rescues cells from abnormal endosome buildup [52]. Conditions that promote 
autophagy divert MVB to the lysosome rather than the plasma membrane, thus 
inhibiting exosome release [53]. On the other hand, autophagy defects, such as 
in neurogenerative diseases, promote release of oxidized protein aggregates via 
exosomes [54]. In addition, chemical or genetic inhibition of the phosphoinositide 
kinase PIKfyve, a key enzyme in membrane autophagy trafficking, promotes the 
release of exosomes that contain proteins related to autophagy [55]. 
Microvesicles (MVs) Biogenesis 
Microvesicles are EVs that originate from the plasma membrane. The 
formation of microvesicles involves rearrangement of plasma membrane 
phospholipids and reorganization of the underlying cytoskeleton. An initial factor 
that promotes microvesicle formation is an increase in intracellular Ca2+, which is 
driven by oxidative stress [56]. Increased Ca2+ inhibits inward aminophospholipid 
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translocase (flippase) and activates an outward translocase (floppase). This 
aberrant phospholipid translocation leads to an externalization of 
phosphatidylserine (PS), a general characteristic of MV [57]. However, some 
MVs do not have PS on the outer membrane leaflet [58]. Ca2+ overload also 
activates caspases that lyse the cytoskeleton making it dissociate from the 
plasma membrane at the budding site. MV pinch-off involves a cascade of 
signaling that is triggered by the GTP-binding protein ADP-ribosylation factor 6 
(ARF6). ARF6 activates phospholipase D leading to phosphatidic acid 
generation, which recruits extracellular signal-regulated kinase (ERK) to the 
plasma membrane. ERK subsequently phosphorylates myosin light-chain kinase 
(MLCK), which further phosphorylates the myosin light chain (MLC). This 
signaling cascade results in actomyosin-based contraction at the neck of the bud 
leading to MV release [59].  
Apoptotic Bodies Biogenesis 
Unlike exosomes and MV formation, apoptotic bodies are generated by 
dead cells. However, a common pathway observed in both apoptotic body 
formation and MV formation is MLC phosphorylation, which is responsible for 
membrane protrusion. Instead of an ARF-6 mediated process, membrane 
blebbing of apoptotic cells is initiated by caspase-3 activation, which cleaves and 
activates Rho-associated coiled-coil protein kinase 1 (ROCK-1), an enzyme that 
phosphorylates MLC [60]. Because caspase activation causes DNA cleavage 
and cytochrome c release from mitochondria, the remnants of this process, such 
as nuclear DNA and mitochondrial fragments, can be found in apoptotic bodies. 
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EVs as a Biomarker for Oxidative Stress-Related Diseases 
DOX generates extensive quantities of oxidized and ubiquitinated proteins 
while it disrupts multiple pathways of protein quality control as discussed above. 
Because EV biogenesis and protein quality control pathways are interconnected, 
EVs serve as an alternative pathway to remove toxic proteins from cells during 
DOX-induced oxidative stress. Indeed, DOX can promote EV release in several 
ways. DOX activation of p53 can increase MVB production via TSAP6 activation 
[48,61]. In addition, DOX disrupts Ca2+ homeostasis in cardiomyocytes by 
interfering with the electron transport chain leading to the potential collapse of the 
mitochondrial membrane [62]. Inability to maintain mitochondrial membrane 
potential inhibits Ca2+ influx into mitochondria, which results in an elevation of 
cytosolic Ca2+, a key event that induces MV release. Lipid peroxidation by DOX 
may affect membrane curvature and promote EV formation as evidenced by 
photooxidation of artificial lipid membrane inducing alteration of its physical 
property, in which the hydroperoxyl group increases the area of lipid membrane, 
thus creating membrane budding [63]. The effect of DOX on protein quality 
control pathways as well as EV biogenesis is summarized in Figure 1.1. 
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Figure 1.1 DOX inhibits intracellular protein quality control 
pathways while promoting extracellular vesicle release  
DOX redox cycling at complex I leads to excessive ROS and RNS 
generation in mitochondria, which leads to oxidation of a variety of 
biomolecules (1). 4HNE is a reactive lipid peroxidation product that 
can adduct to proteins and inactivate protein function (2). Oxidized 
proteins as well as 4HNE-adducted proteins are subject to 
degradation by protein quality control pathway including protein 
unfolding, ubiquitin-proteasome pathway, and autophagy. Severe 
protein oxidation due to DOX insults generates bulky misfolded 
proteins, which overwhelm proteasome degradation, thus forming 
protein aggregates (3). Autophagy is a major pathway to remove 
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and recycle protein aggregates, as well as damaged organelles 
such as mitochondria. DOX inhibits VATPase, a proton pump that 
maintains lysosomal pH, as well as LAMP2A, a membrane 
transporter of oxidized protein into lysosomal lumen for degradation 
(4). Lysosomal dysfunction leads to an accumulation of oxidized 
proteins, which can be alternatively sorted into MVB by ESCRT 
complexes (5), as well as HSC70 (6). DOX-induced DNA damage 
activates p53, which upregulates TSAP6, an endosomal membrane 
protein responsible for MVB formation (7). Exosomes are 
generated by fusion of MVB with the plasma membrane, and 
release of the intraluminal vesicles into extracellular space (8). 
DOX blocks mitophagy via p53-mediated PINK1 sequestration into 
cytosol, thus preventing autophagosome formation (9). 
Dysfunctional mitochondria that cannot be cleared by autophagy 
accumulate (10). Meanwhile, mitochondrial dysfunction induces 
Ca2+ retention in cytoplasm (11), which in turn inhibits flippase and 
activates floppase (12). PS externalization occurs due to floppase 
activity (13). Increases in cytosolic Ca2+ also activate caspases, 
which cleaves cytoskeleton and dissociates the membrane from 
underlying structure, forming MVs (14). Adapted from Yarana et al. 
Antioxidants (Basel). 2017 Sep 28;6(4) 
Since the mechanisms by which DOX promotes EV release are based 
primarily on oxidative stress, it follows that this concept can be applied to other 
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chemotherapeutic agents that generate ROS/RNS as well. In fact, Hall and 
colleagues found a significant increase in endothelial-derived MVs in the blood of 
multiple myeloma patients treated with cyclophosphamide, thalidomide / 
lenalidomide and dexamethasone when compared to baseline [64]. In addition, 
cancer cells exploit EVs to remove intracellular chemotherapeutic drug and 
promote chemoresistant phenotype. Recently, Muralidharan-Chari and 
colleagues reported that human pancreatic cancer cells release MVs to expel 
gemcitabine—a chemotherapeutic that inhibits DNA synthesis. The ability of cells 
to release MV for gemcitabine clearance correlated with the degree of drug 
resistance, and inhibition of MV release sensitized the cells to gemcitabine [65].  
For many reasons, EVs are more attractive for biomarker discovery than 
conventional serum biomarkers. In addition to their stability and ability to carry a 
variety of biomolecules, as discussed above, EVs are abundant in a variety of 
body fluids, including blood, urine, saliva, milk, lymph, ascites, and amniotic 
fluids. EVs that are released from viable tissues in the form of exosomes and 
MVs serve as useful tools of early markers of tissue injury that are detectable 
prior to cell death. Since EVs are highly associated with tissue redox status, a 
study of oxidatively modified molecules will be beneficial for biomarker discovery 
of oxidative stress-mediated diseases, especially chemotherapy-induced tissue 
injury, where early cardioprotective intervention is a goal. Figure 1.2 shows 
potential EV cargo that could be used as a biomarker for oxidative stress and 
potential methods to identify those markers. 
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Figure 1.2 Candidate molecules in EVs for oxidative stress 
biomarkers 
Adapted from Yarana et al. Antioxidants (Basel). 2017 Sep 28;6(4) 
Cellular oxidative stress leads to the production of oxidatively modified 
molecules such as oxidized lipids, oxidized proteins and mitochondrial DNA 
(mtDNA) fragments, which are sorted to EVs for removal. Those oxidized 
molecules as well as apoptotic nuclear DNA (nDNA) and tissue specific proteins, 
mRNA and miRNA, can identify the origin as well as the oxidative status of the 
releasing cells. Several methods, such as lipidomics, redox proteomics, RNA 
microarray, PCR, and gene sequencing, can be applied to discover the potential 
molecule to be used as a certain disease biomarker. 
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Functions of EVs under Oxidative Stress Response 
EVs play a key role in mediating cell-cell communication. They shuttle 
bioactive lipids, mRNA, miRNA, as well as signaling proteins that drive biological 
changes in recipient cells. EVs have advantages over other types of intercellular 
communication because the signaling molecules inside them are protected from 
enzymatic degradation. Thus, the messages can be delivered to sites away from 
the releasing spot. The messages can also be delivered with high specificity to 
recipient cells via receptor-mediated endocytosis [66]. Intercellular 
communication via EVs is critical to the progression of many oxidative stress-
related diseases, among them: cancer-microenvironment crosstalk—a key event 
in cancer progression and metastasis [67]; spreading toxic protein aggregates in 
neurodegenerative diseases [68]; and carrying damage and pathogen-associated 
molecular patterns (DAMPs and PAMPs), autoantigens, and proinflammatory 
cytokines to activate immune cells in inflammatory diseases [69]. In this review, 
we discuss the role of EVs in the context of oxidative stress. 
Table 1 summarizes the effect on recipient cells of EVs released under 
different oxidative stress conditions. Briefly, oxidative stress conditions determine 
the contents of EVs. Those contents can induce an oxidative stress response in 
recipient cells either by helping to protect the releasing cells against further injury 
or by exacerbating the injury. Although EVs serve as a compensatory 
mechanism that deal with proteotoxicity, the consequences of proteotoxic cargo 
transference to neighboring cells can be detrimental. Malik et al. have shown that 
ROS induction in adult rat cardiomyocytes treated with ethanol or brief 
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hypoxia/reoxygenation conditions leads to HSP60-containing exosome release 
as HSP60 causes cardiomyocyte apoptosis [70]. However, spreading HSP60 by 
exosomes to neighboring cells could activate Toll-like receptor 4 (TLR4)-
mediated apoptosis in the recipient cells [71]. In contrast, Eldh et al. reported that 
mRNA profiles in exosomes change when mast cells are treated with H2O2 and 
the exosomal mRNA helps mast cells tolerate higher doses of H2O2 [72]. Retinal 
pigment epithelial cells treated with ethanol release exosomes that contain 
vascular endothelial growth factor receptor as well as the mRNA of the protein, 
and these exosomes promotes angiogenesis [73].  
Table 1.1 Role of oxidative stress-related EVs on cell viability and tissue 
inflammation 
Cell / tissue 
type of 
origin 
EV type Oxidative 
stress 
condition 
Oxidative 
stress-
related 
cargo 
Effect Referen
ce 
Cardiomyocyt
es 
Exosomes Ethanol, 
hypoxia / 
reoxygenati
on 
HSP60 TLR4-
mediated 
apoptosis 
Heiserm
an et al. 
[68] 
Mast cells Exosomes H2O2 mRNA H2O2 
tolerance 
Eldh 
et al. [69] 
Retinal 
pigment 
epithelial 
cells 
Exosomes Ethanol VEGF 
protein and 
mRNA 
Angiogene
sis 
Atienzar-
Aroca 
et al. [70] 
HEK293 cells Exosomes 
+ 
Microvesicl
es 
Ca2+ 
ionophore 
(Lipoxygena
se 
stimulator) 
Oxidized 
phospholipi
ds 
TLR4-
mediated 
NFκB 
activation 
Mancek-
Keber 
et al. [71] 
Liver Microvesicl
es 
High fat diet 
treated mice 
(NASH 
model) 
Oxidized 
mtDNA 
TLR9-
induced 
TNFɑ, IL-6 
production 
Garcia-
Martinez 
et al. [72[ 
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Liver Microvesicl
es 
Chronic plus 
binge 
alcohol 
drinking 
mtDNA TLR9-
mediated 
neutrophilic 
inflammatio
n 
Cai et al. 
[73] 
Liver Exosomes Alcoholic 
hepatitis 
miR-122 Sensitize 
monocytes 
to LPS 
Momen-
Heravi 
et al. [74] 
Liver Microvesicl
es 
Saturated 
fatty acid-
induced 
lipotoxicity 
TRAIL DRS-
dependent 
macrophag
e activation 
Hirsova 
et al. [75] 
Macrophage Exosomes Myocardial 
infarction 
miR-155 Fibroblast 
inflammatio
n 
Wang 
et al. [76] 
Cardiosphere
-derived cells 
EVs Myocardial 
infarction 
Y RNA 
fragment 
IL-10 
expression 
and 
secretion 
Cambier 
et al. [77] 
Adapted from Yarana et al. Antioxidants (Basel). 2017 Sep 28;6(4) 
EVs are well-known to function as an immunomodulator. EVs can present 
cellular peptide antigen on their surface with major histocompatibility complex 
(MHC) class I and class II molecules. The peptide antigen can activate T-cells 
directly or indirectly by transfer to antigen-presenting cells. Accumulating 
evidence indicates that EVs released under an oxidative stress condition can 
stimulate immune cells. EVs from HEK293 cells treated with a Ca2+ ionophore 
(A23187) or synthetic EVs treated with 15-lipoxygenase and Fenton reaction 
contain lipid peroxidation products on their surface. These stress EVs activate 
TLR4-mediated NFκB signaling and pro-inflammatory cytokine release from 
macrophages [74]. Plasma from mice fed with a high fat diet contains oxidized 
mtDNA-carrying MVs, which can induce TNFα and IL-6 production through TLR9 
activation [75]. Oxidative stress in an alcoholic hepatitis model contains mtDNA 
in hepatocyte-derived MVs, which can also activate TLR9 and promote 
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neutrophilic inflammation [76]. Another alcoholic hepatitis model presented 
hepatocyte release exosomes with miR-122, a liver-specific miRNA. The miR-
122 in exosomes is biologically active in that it can inhibit heme oxygenase-1 
making the monocyte more sensitive to LPS-induced TNFα and IL-1β production 
[77]. Mouse and human hepatocytes treated with palmitate to induce lipotoxicity 
release MVs that express TNF-related apoptosis-inducing ligand (TRAIL) on their 
surface, which are recognized by death receptor 5 on macrophage resulting in IL-
6 release [78]. Immune cells can receive EVs-induced cytokine production signal 
from non-immune cells. Wang et al. recently reported that myocardial infarction 
induces macrophages to release exosomes-containing miR-155, which can 
transfer to cardiac fibroblasts. This event leads to a downregulation of the 
suppressor of cytokine signaling 1 (SOCS1)—a negative regulator of cytokine 
signaling—thus promoting cardiac inflammation [76]. However, a recent study 
from Cambier et al. found that the most abundant RNA in EVs released during 
myocardial infarction from cardiosphere-derived cells are Y RNA fragment, a 
small non-coding RNA. Delivery of Y RNA to macrophages upregulates IL-10 
and protects cardiac tissue from ischemia/reperfusion injury [79]. 
Superoxide Dismutase and EV-Mediated Oxidative Stress Response 
Superoxide dismutase (SOD) is a compartmentalized ROS detoxifying 
enzyme that catalyzes the dismutation of O2•- to H2O2 and O2 [80,81]. Three 
isoforms of SOD have been characterized in mammals. SOD1 (CuZnSOD) is a 
homodimer that contains Cu and Zn at the catalytic cite. CuZnSOD is located 
ubiquitously in cytoplasm, the mitochondrial intermembrane space, nucleus, and 
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lysosome. SOD2 (MnSOD) is a Mn-containing homotetramer enzyme with a 
mitochondrial localization sequence that makes it reside in the mitochondrial 
matrix. SOD3 (ECSOD) is a Cu and Zn-containing homotetramer enzyme 
localized on the cell surface by interaction of its C-terminal region with heparin 
and other extracellular matrix proteins [82,83]. ECSOD can be detected in body 
fluids such as plasma, lymph, ascites, synovial fluid, and cerebrospinal fluids 
[84,85]. SOD plays a role in cell signaling under physiological as well as 
pathological conditions. Recent studies have begun to reveal the interplay 
between SOD and the EVs pathway. A discussion of the relationship between 
SOD and EVs in the context of EVs-associated oxidative stress response follows. 
SOD1 
The SOD1 gene is located on chromosome 21 (21q22.1 region). The 
SOD1 activity of a person with Down syndrome (trisomy 21) is 50% higher than 
in the normal population. Although the mechanism of how SOD1 promotes the 
Down syndrome phenotype is unknown, one possible explanation is an increase 
in ratio of SOD1 activity over glutathione peroxidase 1 activity, which leads to 
overproduction of H2O2—a key senescence mediator [86]. The well- established 
link between SOD1 and human disease is typified by the development of 
amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized 
by the progressive loss of motor neurons in the corticospinal tract involving brain, 
brainstem, and spinal cord. SOD1 mutations account for 1-4% of sporadic ALS 
patients and 20% of familial ALS patients [87]. The SOD1 mutation interferes 
with protein stability and folding, which leads to protein aggregation [88]. The 
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aggregated SOD1 can be transferred to other neurons by contiguous 
propagation to the neighboring neurons or by network propagation of synaptic 
transmission [89]. Grad and colleagues found that aggregated SOD1 can be 
released extracellularly with or without exosome association. The free SOD1 or 
the exosome-associated SOD1 can be taken up by recipient cells. However, 
many questions remain to be clarified in exosome-mediated SOD1 transfer. For 
instance, how is aggregated SOD1 sorted into MVB, and is the SOD1 in the 
exosomes degraded in the recipient cells by the lysosomal pathway or does it 
cause proteotoxicity in the recipient cells? 
SOD2 
SOD2 is located exclusively within mitochondria. Its major role is to protect 
mitochondria from the damaging effects of O2 [33]). Mice with a complete SOD2 
knockout mice die in early post-natal life due to dilated cardiomyopathy [90]. Life-
long heterozygous deletion of SOD2 in mice reduces 50% of SOD2 activity and 
leads to oxidative damage in all tissues, as evidenced by an elevation of 8-OHdG 
in nuclear and mtDNA. Although aging is not affected by partial SOD2 deletion, 
the mice have a two-fold higher incidence of developing tumors and 80% have 
multiple tumors, including lymphoma, hemangioma, adenocarcinoma, and 
pituitary adenoma [91].  
Excessive ROS generation from mitochondria is a major mechanism of 
DOX-induced cardiotoxicity. Our lab previously discovered that SOD2 
overexpression protects heart tissue from DOX-induced mitochondrial injury [92]. 
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In those animals, mitochondrial complex I is spared from O2•- insult [93]. 
Mitochondrial iron is a critical mediator of cardiotoxicity from DOX. Dexrazoxane, 
an iron only chelator that is FDA-approved for use as a cardioprotective agent 
against DOX toxicity, is more effective than other iron chelators since it can 
reduce mitochondrial iron [94]. SOD2 affects mitochondrial iron similarly to the 
effect of dexrazoxane. In mice, loss of SOD2 from erythroid progenitor cells 
results in accumulation of mitochondrial iron leading to protein oxidation and 
membrane deformity—a phenotype similar to ringed sideroblasts in hemolytic 
anemia [95]. 
As discussed above, oxidative stress and impaired protein quality control 
drive EV release, which in turn can promote further tissue damage and tissue 
inflammation. Although the direct effect of SOD2 on EVs oxidative stress 
response has not yet been investigated, we speculate that SOD2, which limits 
ROS production, can reduce oxidative stress-related tissue injury during the first 
wave of chemotherapy insult, as well as prevent the second wave of injury 
mediated by damaging cell-derived EVs.  
SOD3 
SOD3 is a secretory CuZnSOD. The human SOD3 gene is localized on 
the 4p-q21 region of chromosome 4 [96]. It shares 60% homology with the SOD1 
gene but very low homology with the SOD2 gene. Human SOD3 mRNA is highly 
enriched in certain tissues, including heart, placenta, pancreas, and lung, and 
less enriched in kidney, skeletal muscle, liver and brain [97]. As it is located on 
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cell surface and in the extracellular matrix, SOD3 plays a major protective role 
against oxidative damage in the extracellular environment. NO in the 
extracellular environment is crucial for maintaining cardiovascular homeostasis. 
NO regulates vascular tone; inhibits platelet aggregation and leukocyte 
adhesion; and prevents vascular inflammation. O2•- generated by Xanthine 
oxidase, NADPH oxidase, and uncoupled endothelial nitric oxide synthase 
interacts with NO forming ONOO-, which in turn oxidizes various biomolecules 
leading to vascular dysfunction. SOD3 promotes bioavailability of NO by 
removing the inhibitory O2•- molecule thus helping to maintain vascular function 
[83].  
A recent study by Iversen and colleagues revealed that SOD3 can also 
reside in the intravesicular compartment of neutrophil in a resting state and be 
released as a cargo of EVs when neutrophil is stimulated by formyl-methionyl-
leucyl-phenylalanine or phorbal 12-myristate 13-acetate. The function of SOD3 in 
EVs is preserved as EVs containing SOD3 can reduce O2•- in extracellular space 
[98]. Indeed, neutrophils lack SOD3 mRNA. Thus, SOD3 in vesicles might 
originate from other cells, transfer to neutrophil plasma membrane, and 
subsequently are stored in endosomes ready for secretion when needed. 
However, the original source of transferred SOD3 and the mechanism of how 
SOD3 is taken up by neutrophils into secretory vesicles have not been 
investigated. Understanding SOD3 transfer and storage by the EVs mechanism 
may help develop a new therapeutic intervention for use of EVs as a vehicle to 
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transfer SOD3 to the tissues that require this antioxidant enzyme but have limited 
capacity to generate their own SOD3. 
DOX-Induced Cardiomyopathy and Inflammation 
The innate immune system plays a key role in regulating inflammation 
during the progression of heart failure [99]. Proinflammatory cytokines, especially 
TNFα, correlate very well with clinical symptoms of the patients [100]. Cardiac 
inflammation also occurs in DOX-induced cardiomyopathy. Inflammatory cell 
infiltration into heart tissue and the increase in plasma level of TNFα are 
associated with left ventricular dysfunction induced by DOX [101]. However how 
myocardial injury is sensed by the innate immune system to initiate inflammation 
is not fully understood. 
EVs and Immune Cells 
EVs are known to regulate innate and adaptive immune influences to 
execute both pro- and anti-inflammatory responses [102,103]. Most of studies 
focused on the role of EVs on immune cells in response to pathological stress 
such as injury, infection, cancer, and inflammatory diseases. On one hand, EVs 
can activate innate immune cells by transferring a wide variety of pro-
inflammatory cytokines including: IL-1 beta; inflammasome component caspase-
1 [104]; enzymes that generate ROS such as NADPH oxidase [105,106]; 
bioactive lipids such as eicosanoids and their synthesizing enzymes 
cyclooxygenase and lipoxygenase [107]; miRNAs; pro-inflammatory mediators 
such as platelet-activating factor [108] and TNF receptor [108]. EV-bearing 
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antigen on major histocompatibility complexed class I (MHC-I) and class II (MHC-
II), can activate CD8+ and CD4+ T lymphocytes, respectively. The ability of EVs 
to activate an immune response has been utilized for vaccine development 
against cancer [109] and microbial infections [110]. However, for inflammatory 
disease treatment, the pro-inflammatory EV effects need to be inhibited. Despite 
much evidence demonstrating EV pro-inflammatory effects, EVs from certain cell 
types are immunosuppressive. For instance, EVs from stem cells have 
immunosuppressive properties and promote tissue repair and regeneration 
mediated by anti-inflammatory transcription factors, mRNA, cytokines, enzyme, 
and growth factor [111]. EVs from tumor cells have an ability to escape immune-
mediated cytotoxicity by expressing membrane-associated proteins such as 
FasL, which can induce T lymphocyte cell death through activation of TNF 
receptor I and Fas receptor [112], TGF beta and heat shock protein 72. These 
factors activate regulatory T cells and Natural Killer Group 2D ligand, which 
impair natural killer cell and CD8+ T cell function by a decoy effect, as well as 
mRNA, miRNA and proteins that inhibit myeloid cell differentiation [113]. 
Macrophage Polarization in Tissue Injury and Tissue Repair 
Macrophages are mononuclear phagocytic cells that play a critical role in 
the innate immune response. Macrophages not only serve as a primary defense 
mechanism to remove pathogens, toxicants and tissue debris, but also govern 
inflammatory resolution and wound healing. To accomplish those functions, 
macrophages must reprogram themselves to obtain different phenotypes called 
macrophage polarizations. Macrophage polarizations are generally categorized 
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into 2 extreme phenotypes, M1 and M2. M1 is a pro-inflammatory phenotype 
characterized by a high expression of pro-inflammatory cytokines such as TNF 
alpha, IL-6, and IL-1beta. M1 expresses high levels of inducible nitric oxide 
synthase that generates nitric oxide to promote inflammation. For cellular 
metabolism, M1 relies more on glycolysis than oxidative phosphorylation. In 
contrast, M2 is an anti-inflammatory phenotype that suppresses inflammation 
and promotes tissue repair. M2 is characterized by a high expression of anti-
inflammatory cytokines such as IL-10 and TGF beta. M2 expresses high anti-
oxidant enzymes and relies more on mitochondrial OXPHOS. The balance of M1 
and M2 function is critical to maintain tissue homeostasis. Excessive or 
uncontrolled M1 macrophages lead to unresolved tissue injury and chronic 
inflammation whereas excessive M2 activation leads to tissue fibrosis [114]. 
Redox Signaling in Macrophage Polarization 
The process of M1 and M2 polarization involves redox regulation of 
transcription factors, which upregulate or downregulate pro- and anti-
inflammatory cytokines, as well as anti-oxidant enzymes that counteract ROS 
and RNS generation during the inflammatory process. The redox regulation can 
occur at the level of their regulatory protein binding step in the cytoplasm or at 
the DNA binding step in the nucleus.  
 Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a 
transcription factor involved in many cellular processes including cell growth, 
differentiation and inflammation. NFκB upregulates pro-inflammatory cytokines, 
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chemokines, and adhesion molecules. In nonstimulated macrophages, NFκB is 
sequestered in the cytosol by interacting with its inhibitory partner IκB, which 
masks the NFκB nuclear localization sequence and prevents NFκB nuclear 
translocation. Oxidative stress can activate NFκB by activating protein tyrosine 
kinase, which subsequently phosphorylates IκB leading to IκB degradation by 
proteasomes releasing NFκB from the inhibitory binding [115]. However, once 
NFκB is translocated into the nuclease, oxidative stress inhibits its DNA binding 
activity via nitrosylation of its cysteine residue, which is prevented by thioredoxin 
[116]. 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) is a key transcription 
factor responsible for a cytoprotective mechanism against oxidative stress by 
enhancing anti-oxidant enzyme gene expression such as heme oxygenase-1 
(HO-1), glutathione S-transferase, glutathione peroxidase, NAD(P)H quinone 
oxidoreductase 1, and peroxiredoxin 1 [117]. Under normal conditions, Nrf-2 
activity is inhibited by interacting with a ubiquitin ligase—Kelch-like ECH-
associated protein (KEAP-1) leading to constitutive degradation of Nrf-2 by 
proteasomes. However, a minimal amount of Nrf-2 can escape KEAP-1 binding 
and localize to the nucleus to regulate basal anti-oxidant capacity. Under 
oxidative stress conditions, the cysteine residues of KEAP-1 are oxidized and a 
conformational changed KEAP-1 releases Nrf-2 from the inhibitory complex 
[118]. Upon binding to an antioxidant responsive element (ARE) in the nucleus, 
Nrf-2 heterodimerizes with a small Maf protein to transactivate the generation of 
anti-oxidant enzymes. Several lines of evidence have shown that the anti-oxidant 
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effect of Nrf-2 plays a key role in anti-inflammatory response [119-121]. However, 
more recent evidence has revealed an anti-inflammatory effect of Nrf-2 
independent of the anti-oxidant effect. Nrf-2 can directly interfere with pro-
inflammatory cytokine gene expression by blocking the recruitment of RNA 
polymerase II to IL-6 and IL-1 beta gene transcription start sites [122].  
NFκB and Nrf-2 interdependently regulate each other by a Yin Yang-like 
signaling. Inhibition of Nrf-2 increases NFκB activity and vice versa. Other than 
Nrf-2, KEAP-1 can also interact with IKK and block IKK phosphorylation activity, 
as well as induce IKK degradation, thus increasing the level of IκB and inhibit the 
NFκB- IκB pathway [123]. HO-1, which is an Nrf-2 target, can directly inhibit 
NFκB without its anti-oxidant property [124]. Lastly, Nrf-2 and NFκB compete to 
bind the co-activator CREB binding protein [125]. 
Thioredoxin (TRX) is a small redox sensitive protein that contains 2 redox-
active cysteine residues in its active site—Cys-32 and Cys—35. TRX maintains 
the reducing environment of the cells by the thiol-disulfide exchange reaction and 
denitrosylation reaction. Moreover, TRX is also involved in an inflammation 
signaling pathway by interacting with proteins that control immune activation 
(Figure 1.3). Two isoforms of TRX have been identified. TRX1 primarily exists in 
cytoplasm but it can be found in the nucleus or secreted out of the cell, while 
TRX2 is located in mitochondria. Although TRX has an overlapping function with 
glutathione (GSH) in controlling redox homeostasis, proteomic analysis revealed 
distinct target proteins from GSH, suggesting selective functions of TRX 
[126,127]. TRX has been shown to have an anti-inflammatory effect by 
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enhancing M2 polarization in the presence of IL-4, as well as decrease the 
inflammatory response induced by LPS [128].TRX1 can regulate NFKB in two 
ways. Cytosolic TRX1 inhibits NFKB activation by preventing the dissociation of 
IκB from NFκB [129].  
However, if NFKB is translocated into the nucleus, TRX1 can promote the 
NFκB DNA binding activity by preventing NFκB nitrosylation [130] and disulfide 
bond formation at cysteine 62 of p50 subunit [116]. TRX1 can also regulate 
NLRP3 inflammasome activation. TRX1 inhibits NLRP3 inflammasome by 
interacting with thioredoxin-interacting protein (TXNIP) and prevent binding and 
activation of TXNIP to NLRP3 inflammasome [131]. Furthermore, TRX1 can also 
regulate Nrf-2 pathway. Direct interaction of TRX1 with Nrf-2 interacting protein, 
Kelch-like ECH-associated protein (KEAP-1), maintains KEAP1 in a reduced 
state thus preventing Nrf-2 nuclear translocation [132]. However, nuclear TRX1 
has opposing function in promoting Nrf-2 transcription activity by keeping 
cysteine 506 of Nrf2 in the reduced state [133]. 
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Figure 1.3 Regulation of Nrf-2 and NFκB by TRX1 
Depending on its location, TRX1 regulates Nrf-2 and NFκB in the 
opposite ways. Cytosolic TRX1 inhibits Nrf-2 and NFκB activation 
by promoting the association of Nrf-2 with KEAP-1 and NFκB with 
IκB thus blocking Nrf-2 and NFκB nuclear translocation. In contrast, 
nuclear TRX1 promotes Nrf-2 binding to antioxidant response 
element (ARE) and NFκB binding to its response element (NFκB -
RE) since TRX1 maintain Nrf2 and NFκB reduced state, which 
leads to the upregulation of antioxidant genes and pro-inflammatory 
genes.  
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Research Objective 
The aims of this study are to investigate whether EVs could be used as a 
biomarker for DOX-induced cardiotoxicity and identify the effects of EVs on the 
innate immune response during DOX treatment.  
In chapter two, we report the characteristics of serum EVs released after 
DOX treatment in mice, the tissue specific markers that indicate the major 
sources of those EVs, the levels of oxidative stress marker—protein-bound 
4HNE—in the EVs, as well as evaluate the potential of EVs to predict 
cardiotoxicity from DOX.  
In chapter three, we report the functions of EVs released from different 
normal tissues exposed to DOX on macrophages. Our study investigated how 
EVs from the tissues that have different levels of oxidative stress mediate 
different effects on macrophage polarization, focusing on redox sensitive 
molecule regulation. 
The results from this study provide a novel, clinically applicable biomarker 
that is superior to the conventional biomarker for DOX-induced cardiotoxicity. 
Moreover, understanding the effects of EVs on macrophages will identify a new 
target for treatment of DOX-induced tissue injury mediated by innate immune 
activation. 
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CHAPTER 2. CIRCULATING EXTRACELLULAR VESICLES IN A 
DOXORUBICIN-INDUCED CARDIAC INJURY MOUSE MODEL CONTAIN 
PROTEIN BIOMARKERS OF EARLY CARDIAC INJURY. 
Overview 
Significant advances in the efficacy of cancer therapy have been 
accompanied by an escalation in side effects that result from therapy-induced 
injury to normal tissues. The number of cancer survivors is now 15.5 million in 
the United States alone, and is expected to rise by 31% to 20.3 million by 2026 
(www.cancer.org). Cardiac injury is a major cause of death in cancer survivors, 
but the current indicators of cardiac injury are detectable only after significant 
damage has occurred. Thus, sensitive biomarkers are needed to permit early 
intervention to prevent long-term cardiac injury after chemotherapy. In response 
to stress conditions, tissues release extracellular vesicles into circulation. Using a 
mouse model of DOX-induced cardiac injury, we quantified serum EVs, analyzed 
proteomes, measured oxidized protein levels in serum EVs released after DOX 
treatment, and investigated the alteration of EV content. 
We found that treatment with DOX caused a significant increase in 
circulating EVs (DOX_EVs) compared to saline-treated controls. DOX_EVs 
exhibited a higher level of 4-hydroxynonenal adducted proteins, a lipid 
peroxidation product linked to DOX-induced cardiotoxicity. Proteomic profiling of 
DOX_EVs revealed the distinctive presence of brain/heart, muscle, and liver 
isoforms of glycogen phosphorylase (GP), and their origins were verified to be 
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heart, skeletal muscle, and liver, respectively. The presence of brain/heart GP 
(PYGB) in DOX_EVs correlated with a reduction of PYGB in heart, but not brain 
tissues. Manganese superoxide dismutase (MnSOD) overexpression as well as 
pretreatment with cardioprotective agents and MnSOD mimetics resulted in a 
reduction of EV-associated PYGB in mice treated with DOX. Kinetic studies 
indicated that EVs containing PYGB are released prior to the rise of cardiac 
troponin in the blood after DOX treatment, suggesting that PYGB is an early 
indicator of cardiac injury. 
Introduction 
Chemotherapy can damage normal cells as well as cancer cells, and can 
therefore result in late onset of side effects that compromise patient survivorship 
and quality of life. According to the American Cancer Society’s Surveillance and 
Health Services Research, as of 2014, around 6 million cancer survivors had 
lived longer than ten years since their diagnosis (American Cancer Society, 2014 
available from: http://www.cancer.org). Although they survived their cancer, these 
patients may unfortunately suffer from complications of treatment, ranging from 
non-fatal conditions such as cognitive dysfunction, neuropathy, and infertility, to 
life-threatening conditions such as cardiomyopathy, myelodysplastic syndrome, 
and secondary malignancy [134]. Severe adverse effects of chemotherapy can 
also have a substantial economic impact due to hospitalizations and 
prescriptions, costs for which are estimated at around $12,907 and $1,908 per 
person per year, respectively [135]. This estimation reaffirms the significance of 
preventing cancer treatment-related adverse effects. 
 
39 
 
With the exception of secondary malignancies, cardiovascular disease is 
the leading cause of death among cancer survivors [136]. Anthracyclines, 
especially DOX, are the most common chemotherapeutic agents that cause 
cardiomyopathy. However, their effectiveness and broad efficacy against more 
types of cancer than any other class of chemotherapy make anthracyclines a 
frequently used drug class [137].  
DOX-induced cardiomyopathy presents as a decline of left ventricular 
function that can develop many years after treatment cessation [5]. Cardiac 
troponin-I (cTnI) and troponin-T (cTnT) are validated serological biomarkers for 
DOX-induced cardiotoxicity. Although these biomarkers are specific in predicting 
adverse outcomes from high-dose radiation and chemotherapy, the evidence for 
low and moderate doses, as well as in asymptomatic childhood cancer survivors, 
remains unclear [138,139]. Moreover, they are released after cardiac cell death 
occurs, which is not an early event in the development of chemotherapy-induced 
cardiotoxicity. Thus, it is not optimal to start cardioprotective interventions based 
on cTnI or cTnT levels.  
DOX-induced cardiotoxicity and other normal tissue injury begin with the 
generation of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), predominantly in the mitochondria [13,92]. Excess ROS/RNS results in 
oxidative damage to biomolecules such as lipids, DNA, and proteins. Oxidative 
modification of lipids and proteins leads to mitochondrial dysfunction [14] and 
consequently activates cell death pathways [15]. To maintain cellular 
homeostasis, the cells can remove oxidized proteins in several ways, e.g., 
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through ubiquitin/proteasome-mediated degradation, autophagy, and 
extracellular vesicles (EVs). However, recent evidence has shown that extensive 
and sustained oxidative stress during chemotherapy impairs cellular ability to 
degrade oxidized proteins via the ubiquitin/proteasome and autophagy pathways 
[25,34,140]. Therefore, EVs could be a major mechanism for oxidized protein 
elimination during chemotherapy-induced tissue injury. We hypothesized that 
circulating EVs could indicate the level of oxidative stress in targeted tissue 
during chemotherapy and that they could be used as a liquid biopsy for highly 
sensitive biomarkers of tissue injury resulting from chemotherapy. 
EVs are membrane-bound structures released from most cell types into 
the extracellular compartment. EVs are categorized into three types, based on 
size and the mechanisms of biogenesis. Exosomes (50-100 nm) originate from 
inward budding of the endosomal membrane, forming multivesicular bodies, and 
are released by fusion of the multivesicular body membrane with the plasma 
membrane. Microvesicles (0.2-2.0 m) are derived from plasma membrane 
blebbing. Apoptotic bodies (1-2 m) are membranous globules released during 
apoptotic processes [141].  
EVs are attractive for biomarker discovery for many reasons. First, EVs 
are stable in the extracellular environment because of the lipid bilayer that 
protects their cargo from enzymatic degradation [142]. Second, EVs are highly 
abundant in plasma/serum, with an estimated concentration around 1010 EVs per 
mL [143]. Third, EVs carry proteins, lipids, and nucleic acids that reflect their 
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tissues of origin and the condition of the releasing cells [19,144]. However, little is 
known about the oxidative status, content, or tissue origin for circulating EVs 
generated by chemotherapy-induced tissue injury.  
In the present study, we investigated the protein content of EVs to 
determine the potential profile for early detection of cardiac injury after DOX 
treatment. We found that EVs present after DOX treatment contained signatures 
of cardiac tissue and high levels of protein-bound 4-hydroxynonenal (4HNE), 
which can be alleviated by enhancing tissue antioxidant capacity. Moreover, the 
EVs and their protein contents are more sensitive than conventional serological 
biomarkers for detection of DOX-induced tissue injury. 
Materials and Methods 
Animals  
Male C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, 
ME). All mice had free access to food and water and were maintained on an 
automatically timed 12 hour:12 hour dark cycle. All mouse-related procedures 
followed the American Veterinary Medical Association Guidelines for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky. 
Treatment 
The normal (non-tumor-bearing) mice at the age of 10-12 weeks and 25-
28 gram body weight were injected intraperitoneally (IP) with a single 20 mg/kg 
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dose of doxorubicin hydrochloride (DOX; Bedford Laboratories, Inc., Bedford, 
OH) or saline (SAL). Mouse weights were monitored daily after DOX treatment 
until the animals were euthanized. The mice were euthanized and blood was 
collected at 1, 24, 48 and 72 h from inferior vena cava after treatment. Blood was 
allowed to clot by incubation at room temperature for at least 30 min and 
centrifuged at 1,300 g for 15 min to yield the sera. 
For pretreatment experiments, dexrazoxane (DRZ; Zinecard®, and Upjohn 
Company LLC, Division of Pfizer Inc, NY) was administered at 200 mg/kg IP 30 
min before DOX treatment [145]. The manganese superoxide dismutase 
(MnSOD) mi metic Mn(III) meso-tetrakis(N-(n-butoxyethyl)pyridinium-2-
yl)porphyrin, MnTnBuOE-2-PyP5+ (MnP), was kindly provided by Dr. Ines Batinic-
Haberle and colleagues (Duke University School of Medicine, Durham, NC, 
USA). MnP was injected IP at 2 mg/kg 30 min prior to DOX treatment. 
Serum EV Isolation 
For proteomic analysis, mouse serum EVs were isolated by sucrose 
gradient centrifugation as previously described [146] with modifications. 
Discontinuous sucrose gradient (10-70%) was prepared by slowly layering 
sequentially decreasing sucrose density solutions from 70%, 55%, 40%, 25%, 
and 10% from the bottom to the top of 5 ml ultracentrifuge tube, respectively 
(Figure 2.1). 
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Figure 2.1 Sucrose gradient preparation 
Serum was thawed on ice and centrifuged at 12,000 g for 12 min at room 
temperature to yield platelet-free serum. One ml of platelet-free serum was 
layered on top of a 10-70% sucrose gradient in SW55 tubes (Beckman Coulter 
Inc., Brea, CA, USA) with subsequent centrifugation at 100,000 g overnight. 
Another one ml of platelet-free serum was layered on another sucrose gradient 
tube. The samples from two sucrose gradient tubes were pooled together. 
Fractions three to five from each tube, which contained EV markers CD63 and 
CD81 (Figure 2.2), were collected. Each fraction was diluted in phosphate-
buffered saline (PBS) and EV pellets obtained by centrifugation at 100,000 g for 
70 min. The pellets from each fraction were resuspended in PBS and pooled. 
The pooled suspension was centrifuged at 100,000 g for 70 min to obtain a final 
pellet. 
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Figure 2.2 Sucrose gradient isolation process for proteomics 
analysis.  
(A) Diagram showing the process of EV isolation by sucrose 
gradient method (B) Western blot of EV markers, CD63 and CD81 
of sucrose gradient fraction 1 to 5 (from the top to the bottom) and 
(C) EV verification of isolation process by electron microscopy 
 
45 
 
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr 
1;24(7):1644-1653. 
For all other procedures, ExoQuick precipitation solution (System 
Biosciences, Mountain View, CA, USA) was used to isolate EVs. From 200-250 
μL of mouse serum, cells and cellular debris were pelleted by centrifugation at 
3,000 g for 15 min, and 50-63 μL ExoQuick solution was added to the 
supernatants. The mixture was incubated at 4°C for 30 min, and the EV pellet 
was obtained by centrifugation at 1,500 g for 30 min. The supernatant was 
aspirated, and the residual ExoQuick solution was removed without disturbing 
the pellets after centrifugation at 1,500 g for 5 min. EV pellets were resuspended 
in sterile water or PBS and stored at -80 °C.  
Transmission Electron Microscopy (TEM) 
Fresh, unfrozen EV pellets were resuspended in 2% paraformaldehyde 
and adsorbed onto Formvar-carbon coated grids by applying 5 μl of EV 
suspension on to the grid and let it air dry for 20 min. Then, the grids were 
washed by applying a 50-μl drop of PBS on them. Then filter paper was used to 
remove PBS from the grid. The washing step was repeated three times. After 
that, the samples were fixed with 50-μl drops of 1% glutaraldehyde for 5 min 
followed by the washing step. Then, the grids were stained with 50-μl drops of 
uranyl oxalate, pH 7, for 5 min. Next, the grids were then embedded in 50-μl 
drops of a mixture of 4% uranyl acetate and 2% methylcellulose for 10 min on 
ice. Finally, the excessive fluid on the grids was gently removed by slowly 
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dragging the fluid on Whatman no. 1 filter paper so that only thin films were left 
on the grids. The grids were air dried for 5 to 10 min prior to TEM. EVs were 
visualized by TEM at 80 kV [147].  
EV Quantification and Size Measurement 
EVs in PBS suspension were quantified by measuring protein 
concentration using the bicinchoninic acid method. For size measurement, the 
EV suspension was diluted with PBS to a concentration of 100 µg/mL. The size 
distribution of EVs was evaluated by dynamic light scattering using the Zetasizer 
Nano ZS (Malvern, Worcestershire, UK). The laser was operated at a 173° angle 
with temperature set at 4°C.  
Protein-Bound 4HNE Measurement 
EVs from DOX- or SAL-treated mice (DOX_EVs and SAL_EVs, 
respectively) were lysed with radioimmunoprecipitation assay (RIPA) buffer and 
the lysates were mixed with an equal volume of Laemmli buffer. Protein-bound 
4HNE levels were assessed by slot blot as previously described [148]. The 
protein bands were visualized and the intensities were quantified by Adobe 
Photoshop (San Jose, CA) and Scion Image, respectively. Band intensities for 
protein-bound 4HNE for DOX_EVs were normalized by those obtained from 
SAL_EVs, and reported as a fold change after the treatment.  
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Sample Preparation for Mass Spectrometry (MS) 
EV samples from sucrose gradient centrifugation were lysed with RIPA 
buffer and sonicated at room temperature for 30 sec 3 times. Equal protein 
aliquots (10 µg) from SAL_EV and DOX_EV samples were used for proteomic 
analysis. EV lysates were reduced with -mercaptoethanol and heated to 95°C 
for 5 min. The samples were electrophoresed on an 8% SDS-PAGE gel at 60 V 
for 15 min to allow protein migration into the top of the gel. Next, the gel was 
placed into a clean container and 50ml of SYPRO Ruby gel stain (BIO-RAD) was 
added. The gel with the stain was agitated on an orbital shaker overnight at room 
temperature. The next day, the gel was rinsed in 7% acetic acid for 30 min to 
remove background fluorescence. The stained protein bands were visualized 
using UV transilluminator and were then excised and subjected to liquid 
chromatography/tandem MS (LC-MS/MS) (Figure 2.2A). 
LC-MS/MS 
Proteomic analysis was performed by the University of Kentucky 
Proteomics Core Facility. Protein samples, processed as indicated above, were 
reduced with dithiothreitol, alkylated by iodoacetamide, and digested by a 
standard protocol of in-gel trypsin digestion. Shotgun proteomic analysis was 
used as described previously [149]. The tryptic peptides were subjected to nano-
LC-MS/MS analysis using an LTQ-Orbitrap mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA) coupled with an Eksigent Nanoflex cHiPLC™ system 
(Eksigent, Dublin, CA) through a nano-electrospray ionization source.  
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MS/MS Protein Identification  
The LC-MS/MS data were submitted to a local Mascot server. Proteins 
were identified by Proteome Discoverer (version 1.3, Thermo Fisher Scientific) 
against a Mus musculus taxonomy subset of the Swissprot database. Proteomic 
analysis was performed twice. A decoy database was built and searched. Filter 
settings that determine false discovery rates were used to distribute the 
confidence indicators for the peptide matches. Peptide matches that pass the 
filter associated with the strict false discovery rates (with target setting of 0.01) 
were assigned as high confidence. Peptides that were identified in both 
experiments on either the DOX_EVs or the SAL_EVs were considered 
unambiguous. 
Western Blot Analysis  
EVs or serum samples were lysed with RIPA buffer, mixed in Laemli buffer 
with or without beta-mercaptoethanol, and separated by electrophoresis through 
an 8% SDS-PAGE gel. Proteins were transferred to nitrocellulose membranes. 
The blots were blocked with Odyssey® Blocking Buffer (LI-COR, Lincoln, NE, 
USA) and incubated overnight at 4°C with the primary antibodies. Primary 
antibodies used in this study were: anti-CD63 (1:200; Santa Cruz, Santa Cruz, 
CA, USA); anti-Alix (1:200; Santa Cruz); anti-HSC70 (1:200, Santa Cruz); anti-
brain/heart glycogen phosphorylase (PYGB) (1:500, Abgent, San Diego, CA, 
USA); anti-muscle glycogen phosphorylase (PYGM) (1:500, Bioss, Woburn, MA, 
USA); anti-liver glycogen phosphorylase (PYGL) (1:500, GeneTex, Irvine, CA); 
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anti-vinculin (1:200, Santa Cruz), and anti-tubulin (1:200, Santa Cruz). After 
several washes, the blots were incubated with IRDye® anti-mouse, rabbit, or goat 
secondary antibodies (LI-COR) at a dilution of 1:5000 to 1:10,000 for 1 h at room 
temperature. Washed membranes were scanned and the band intensities 
measured by the Odyssey Imaging System. 
EV Immunoprecipitation 
SAL_EVs, DOX_EVs, and DOX-treated heart tissue (400 µg) were 
immunoprecipitated with 4HNE-coated beads. 4HNE antibody was purchased 
from Abcam (Cambridge, MA). SureBeadsTM protein A magnetic beads 
purchased from Bio-rad (Hercules, CA). The beads at the volume of 100 μl (1 
mg/ml) were magnetized and wash 3 times with PBS containing 0.1% Tween-20 
and incubated with 5 μg of 4HNE antibody for 1 hour at room temperature. After 
the washing step, the beads were incubated with SAL_EVs or DOX_EVs at 4°C 
overnight. The next day, the beads were magnetized and the supernatants were 
collected. Immunoprecipitated EVs were lysed with RIPA buffer. Supernatant 
EVs were lysed with RIPA buffer and concentrated with 3 kDa centrifugal filters 
(MilliporeSigma, Norwood, OH) to get a sample equal in volume to the 
immunoprecipitated EVs. Then all of the sample lysates were mixed with 
Laemmli buffer and boiled at 95°C for 5 min before running gel electrophoresis 
(Figure 2.3).  
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Figure 2.3 Diagram illustrating 4HNE immunoprecipitation of 
serum EVs.  
Serum EVs were immunoprecipitated using magnetic beads coated 
with antibody against 4HNE, which recognizes 4HNE adducted 
proteins on EV surface. After the pulldown process, the EVs would 
be separated into two groups. EVs in the supernatant are the EVs 
without 4HNE adduction on the surface (labelled in blue). EVs 
captured by 4HNE antibody-coated beads are the EVs with 4HNE 
adduction (labelled in red). EVs from both groups were lysed with 
RIPA buffer. After lysis, the supernatant was concentrated with 3K 
centrifugal filter to make it the same volume as the pulldown. Then, 
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the samples were mixed with Laemmli buffer and boiled at 95 C for 
5 min before going through western blotting process. Adapted from 
Yarana et al. Clin Cancer Res. 2018 Apr 1;24(7):1644-1653. 
Measurement of Serum Protein Biomarkers for Tissue Injuries 
Cardiac injury was assessed by measuring serum cTnI levels from SAL- 
and DOX-treated mice. Creatine kinase isoenzyme MM (CKMM) and alanine 
transferase (ALT) were used as biomarkers for skeletal muscle and liver injury, 
respectively. Values were obtained using commercial ELISA kits as follows: cTnI 
(Life Diagnostic, West Chester, PA), CKMM (LifeSpan Biosciences, Seattle, WA), 
and ALT (MyBioSource, San Diego, CA). 
Statistical Analysis 
Differences between means of GP isoforms in tissues and in EVs, as well 
as cTnI, ALT, and CKMM comparing between SAL- and DOX-treated mice were 
analyzed by Student’s t-test. Differences between means for DOX-treated and 
other parameters were analyzed by a two-way ANOVA followed by Tukey’s test. 
P-values <0.05 were considered statistically significant.  
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Results 
DOX_EVs had aberrant morphology and larger size when compared to 
SAL_EVs 
To investigate if DOX treatment affected the characteristics of circulating 
EVs, SAL_EVs and DOX_EVs were visualized by TEM. The morphology of EVs 
observed under high-magnification TEM revealed that SAL_EVs were round, 
membranous structures with a smooth surface. In contrast, the membrane of 
DOX_EVs was irregular and the size of the vesicles was larger than that of 
SAL_EVs (Figure 2.4A). The difference in EV size was confirmed by dynamic 
light scattering analysis, which also showed that DOX_EVs have a broader size 
distribution (13.9 ± 3.5 to 204.0 ± 46.4 nm) compared to SAL_EVs (4 ± 0.6 to 123 
± 34.8 nm) (Figure 2.4B).  
To verify that the pellets from the ExoQuick precipitation were composed 
of EVs, equal amounts of pellets derived from SAL- or DOX-treated mouse 
serum were subjected to immunoblotting to detect the proteins that were 
enriched in the EVs. Proteins specific to EVs include CD63 (a tetraspanin protein 
expressed on cellular membranes, including exosomes and microvesicles) and 
Alix (an endosomal sorting complex required for transport). CD63 and Alix were 
detected in pellets from SAL_EVs and DOX_EVs. However, calnexin, an 
endoplasmic reticulum protein commonly detected in apoptotic bodies, could not 
be identified in the EV samples (Figure 2.5). This result suggests that the pellets 
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from the isolation process represented exosomes and microvesicles but not 
apoptotic bodies. 
 
Figure 2.4 Morphology and size of DOX_EVs were different 
from SAL_EVs 
(A) Representative electron micrograph of mouse serum EVs (high 
magnification, X49,000). The numbers represent the diameter of 
the vesicles. (B) Graphic representation of the distribution in EV 
size. Presented data are the percent intensity of scattered light of 
EVs from mouse serum. Blue line represents SAL_EVs’ size 
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distribution. Red line represents DOX_EVs’ size distribution 
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr 
1;24(7):1644-1653.  
  
Figure 2.5 Western blot of EV markers, CD63 and Alix in 
serum EVs 
Serum EVs from saline-treated and DOX-treated mice contained 
markers for EVs but not apoptotic body marker Calnexin; the cell 
lysate was used as a positive control. Adapted from Yarana et al. 
Clin Cancer Res. 2018 Apr 1;24(7):1644-1653.  
Increased levels of circulating EVs and protein-bound 4HNE after DOX 
treatment  
In order to assess the change in the amount of serum EVs over time, we 
quantified serum EVs by measuring protein levels in the EV pellets isolated from 
equal volumes of serum at 1, 24, and 72 h after treatment. While the amount of 
serum EV protein after SAL treatment remained unchanged, the amount of EV 
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protein significantly increased over time after DOX treatment, beginning at 24 h 
(Figure 2.6A). The increase in serum EV quantity after DOX treatment was 
confirmed by TEM (Figure 2.6B). 
 
Figure 2.6 DOX-treated mouse serum contained more EVs 
than SAL-treated mouse serum 
(A) EV protein levels in 250 l serum from saline-treated (blue line) 
and DOX-treated (red line) mice (mean ± SD, n = 5-6, where n = 
number of 250 l-serum samples used for EV isolation, * p < 0.01 
vs 1 h, # p < 0.01 vs Saline. (B) Representative electron 
micrograph of mouse serum EVs (low magnification, X23,000) at 72 
h post treatment. Adapted from Yarana et al. Clin Cancer Res. 
2018 Apr 1;24(7):1644-1653.  
4HNE is a major lipid peroxidation product that appears in cell membranes 
during oxidative stress. 4HNE is highly reactive and can adduct to biomolecules, 
resulting in functional changes in those molecules. Here we found that circulating 
EVs contained higher protein-bound 4HNE levels after DOX treatment (Figure 
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2.7). The protein-bound 4HNE levels peaked as early as 24 h post-DOX 
treatment and remained higher than SAL-treated controls at 72 h.  
 
Figure 2.7 DOX-treated mouse serum contained higher level 
of protein-bound 4HNE than SAL-treated mouse serum  
Fold change of protein-bound 4HNE in EVs from mice treated with 
saline (SAL) or DOX for 1 h, 24 h and 72 h (mean ± SD, n = 6  * p < 
0.05 vs Saline at the same time point. Adapted from Yarana et al. 
Clin Cancer Res. 2018 Apr 1;24(7):1644-1653. 
Serum EV proteomic profile altered after DOX treatment 
To identify EV protein contents that might indicate the tissues of origin and 
potential function of EVs during DOX-induced tissue injury, we performed 
proteomic analysis of DOX_EVs and SAL-EVs after 72 h of treatment. Figure 
2.8A shows the number of proteins identified in SAL_EVs and DOX_EVs. The 
proteomic profiling identified 197 proteins expressed in both SAL_EVs and 
DOX_EVs. Among the proteins enriched only in SAL_EVs, transferrin receptor 1 
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(TfR1) and class I histocompatibility antigen (MHC-I) were identified with high 
confidence, with ion scores above 50 (Figure 2.8B). In contrast, haptoglobin (Hp) 
and glycogen phosphorylase (GP) isoforms from brain (PYGB), muscle (PYGM), 
and liver (PYGL) were uniquely expressed in DOX_EVs (Figure 2.8C). 
 
 
B. Proteins that are only expressed in SAL_EV 
Protein Protein Name Score Coverage 
Q62351 Transferrin receptor protein 1 884.79 36.04 
P14430 H-2 class I histocompatibility 
antigen, Q8 alpha chain 
57.63 4.29 
P06339 H-2 class I histocompatibility 
antigen, D-37 alpha chain 
57.63 3.92 
P01897 H-2 class I histocompatibility 
antigen, L-D alpha chain 
57.04 3.59 
 
C. Proteins that are only expressed in DOX_EV 
Protein Protein Name Score Coverage 
Q61646 Haptoglobin 231.11 31.70 
Q9WUB3 Glycogen phosphorylase, muscle 
form 
166.80 25.06 
Q8C194 Glycogen phosphorylase, brain 
form 
172.00 12.22 
O88990 Alpha-actinin-3 108.98 3.67 
Q9ET01 Glycogen phosphorylase, liver 
form 
80.71 4.59 
P52480 Pyruvate kinase PKM 59.36 6.97 
Figure 2.8 Proteomic profiling of circulating EVs 
(A) Venn diagram showing the number of proteins found in EVs 
from SAL (blue) and DOX-treated (red) mice. (B) List of proteins 
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found exclusively in EVs from SAL-treated mice. (C) List of proteins 
found exclusively in EVs from DOX-treated mice. Score = ion score 
of the peptide; Coverage = % of protein sequence covered by 
identified peptide. Adapted from Yarana et al. Clin Cancer Res. 
2018 Apr 1;24(7):1644-1653. 
EVs containing tissue-specific GP were released from DOX target tissues 
GP is a tissue-specific protein with isoforms expressed in a tissue-specific 
manner, as indicated by their names. PYGB is highly expressed in heart and 
brain, PYGM is highly expressed in skeletal muscle, and PYGL is highly 
expressed in the liver (Figure 2.9). Because heart/brain, liver and skeletal 
muscle are organs known to be affected by DOX, the presence of these GP 
isoforms in serum EVs might serve as a potential biomarker of DOX-induced 
tissue injury.  
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Figure 2.9 Western blots indicating PYGB, PYGM, and PYGL 
are tissue-specific proteins 
PYGB is highly expressed in heart and brain. PYGM is highly 
expressed in skeletal muscle. PYGL is highly expressed in liver. 
Vinculin and tubulin were used as appropriate positive controls. 
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr 
1;24(7):1644-1653. 
Western blot analysis showed that all three GP isoforms as well as the EV 
marker, HSC70, were enriched in DOX_EVs as compared to total serum (Figure 
2.10A). All isoforms were scarcely detected in the serum, confirming that they 
were highly enriched in the EV fraction rather than released as soluble proteins. 
The existence of PYGB, PYGM, and PYGL inside the EVs was further confirmed 
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by their resistance to proteinase K digestion due to the protection of the lipid 
bilayer (Figure 2.11). These data clearly confirmed the proteomic data, i.e., that 
PYGB, PYGM, and PYGL were only detected in DOX_EVs but not SAL_EVs. 
The levels of PYGB, PYGM, and PYGL were also examined in heart and brain, 
skeletal muscle, and liver tissues, respectively. Upon DOX treatment, PYGB was 
significantly decreased in heart tissue, but not in brain tissue, suggesting that it 
was released from damaged heart tissue of DOX-treated animals (Figure 2.10B 
and 2.10C). This result is consistent with the notion that DOX did not cross the 
blood brain barrier, and thus the brain is not a direct target tissue of DOX. 
Similarly, PYGM levels decreased in skeletal muscle and PYGL decreased in the 
liver after DOX treatment (Figure 2.10B and 2.10C). These results suggest that 
EVs that contained PYGB, PYGM, and PYGL were released from the heart, 
skeletal muscle, and liver, respectively. 
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Figure 2.10 EV-containing glycogen phosphorylase isoforms 
are associated with DOX-induced tissue injuries 
(A) Western blot of PYGB, PYGM, PYGL obtained from EVs 
isolated by sucrose gradient centrifugation and from whole serum 
protein, HSC70 was used as an EV marker and loading control for 
EVs. (B) Western blot of PYGB, PYGM and PYGL levels obtained 
from heart, brain, skeletal muscle and liver lysates isolated from 
Saline- and DOX-treated mice. Vinculin was used as a loading 
control for heart and brain tissues; beta tubulin was used as a 
loading control for skeletal muscle and liver. (C) Graphic 
representation of western blot band intensities of PYGB, PYGM 
and PYGL in the relevant highly enriched tissues and normalized 
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by the appropriate loading control (mean ± SD, n = 6, n = number 
of animals/group, * p < 0.05). Adapted from Yarana et al. Clin 
Cancer Res. 2018 Apr 1;24(7):1644-1653. 
 
Figure 2.11 Western blots confirming the existence of PYGB, 
PYGM, and PYGL in SAL_EVs and DOX_EVs after treatment 
with proteinase K 
Cell lysate was used as a positive control for PYGB, PYGM and 
PYGL detection. IgG and albumin were measured as a reference 
for proteinase K efficiency to digest extravesicular proteins. 
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr 
1;24(7):1644-1653. 
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EVs with 4HNE adduction but not 4HNE-free EVs were released from DOX 
target tissues  
Because EVs can contain oxidative stress markers such as 4HNE-
adducted proteins and tissue-specific proteins such as GPs in the same 
structure, we investigated further if EVs containing protein-bound 4HNE were 
released from specific DOX target tissues. In this way, EVs might reveal their 
tissue of origin and the etiology of cellular stress that induced their release. To 
this end, we immunoprecipitated serum EVs with anti-4HNE antibody and 
compared the tissue-specific GPs in those EVs to the protein profile in EVs that 
did not have 4HNE bound. PYGB, PYGM, and PYGL were detected in 4HNE 
pull-downs but not in the supernatant (Figure 2.12). Moreover, EV markers 
flotillin-1 and HSC70 were more strongly detected in the pull-downs than in the 
supernatant. This result suggested that the majority of circulating EVs are 4HNE-
adducted and that these EVs are released from DOX target tissues that have 
high oxidative stress.  
Next, we investigated if the level of EV-associated protein-bound 4HNE 
can be changed by enhancing antioxidant capacity. First, we measured the level 
of protein-bound 4HNE from serum EVs of MnSOD transgenic (MnSOD Tg) mice 
that express approximately two-fold higher MnSOD level (9) compared to wild-
type mice. In SAL-treated MnSOD Tg mice, the level of EV-associated protein-
bound 4HNE did not differ from wild-type mice. However, after DOX treatment, 
MnSOD Tg mice had significantly lower levels of protein-bound 4HNE than the 
wild-type mice (Figure 2.13A).  
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Figure 2.12 EVs with 4HNE adduction are released from direct 
target tissues of DOX 
Western blot to detect PYGB, PYGM, PYGL, as well as EV markers 
flotillin-1 and HSC70, in 4HNE-immunoprecipitated SAL_EVs and 
DOX_EVs and supernatant. Heart tissue lysate was used as a 
positive control. Adapted from Yarana et al. Clin Cancer Res. 2018 
Apr 1;24(7):1644-1653. 
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Figure 2.13 The release of EVs with 4HNE adduction are 
alleviated by antioxidant enhancement 
(A) The level of EV-associated protein-bound 4HNE from wild-type 
and MnSOD Tg mice after SAL or DOX treatment for 72 h. (B) The 
level of EV-associated protein-bound 4HNE from mice pretreated 
with vehicle, MnP (2 mg/kg) or DRZ (200 mg/kg) 30 min before SAL 
or DOX treatment. (mean ± SD, n = 6-8, n = number of 250 l-
serum samples used for EV isolation, * p < 0.05 vs Saline, # p < 
0.05 vs wild-type DOX) Adapted from Yarana et al. Clin Cancer 
Res. 2018 Apr 1;24(7):1644-1653. 
To determine if exogenously supplied antioxidants can exert a protective 
effect similar to that observed in the transgenic mice, we used two antioxidant-
enhancing drugs, MnP and DRZ, as a tool to study the effect of exogenous 
antioxidants on EV-associated protein-bound 4HNE levels. MnP is a MnSOD 
mimetic, redox-active compound that works similar to endogenous MnSOD and 
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has been shown to protect against DOX-induced cardiotoxicity [15]. DRZ is a 
clinically approved drug for anthracycline-induced cardiotoxicity prevention. DRZ 
acts as an antioxidant by removing iron from iron-DOX complexes [94]. We found 
that MnP pretreatment but not DRZ pretreatment significantly reduced the level 
of EV-associated protein-bound 4HNE when compared to DOX treatment alone 
(Figure 2.13B).  
DOX-induced cardiotoxicity is the most concerning side effect from cancer 
treatment. Since the amount of EVs released is correlated with the degree of 
tissue oxidative stress, we further measured the amount of EVs released from 
heart tissue by using PYGB as a specific cardiac marker. To calculate the total 
amount of EV-encapsulated PYGB (EV_PYGB) in 200 L of serum, the western 
blot band intensities were nomalized by the total amount of EV protein in 200 L 
of serum from each mouse. The result showed that EV released from heart 
tissues as indicated by EV_PYGB in wild-type and MnSOD Tg mice did not 
change after SAL treatment. However, EV_PYGB in DOX-treated MnSOD Tg 
mice was significantly lower than DOX-treated wild-type mice (Figure 2.14A). 
The decrease in serum EV_PYGB was associated with more retention of PYGB 
in heart tissue of DOX-treated MnSOD Tg mice compared to DOX-treated wild-
type mice (Figure 2.14B). Pretreatment with exogenous antioxidants that have 
cardioprotective effects such as MnP and DRZ significantly decreased the level 
of EV_PYGB in DOX-treated mice when compared to DOX treatment alone 
(Figure 2.15A). However, MnP more effectively prevented EV release from heart 
tissue than DRZ (Figure 2.15A). The level of serum EV_PYGB after antioxidant 
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treatment was also associated with the retention of PYGB in heart tissue (Figure 
2.15B). 
 
Figure 2.14 Overexpression of MnSOD prevents the release of 
EV-containing PYGB and promotes the retention of PYGB in 
heart tissues 
(A) Western blot band intensities of PYGB in EVs from 200 µL of 
serum comparing between wild type and MnSOD transgenic mice 
treated with saline or DOX. (B) PYGB normalized to vinculin from 
heart tissues of wild-type and MnSOD Tg mice treated with saline 
or DOX. (mean ± SD, n = 6-8, n = number of 250 l-serum samples 
used for EV isolation, * p < 0.05 vs Saline, # p < 0.05 vs wild-type 
DOX) Adapted from Yarana et al. Clin Cancer Res. 2018 Apr 
1;24(7):1644-1653. 
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Figure 2.15 Pretreatment with MnP or DRZ prevents the 
release of EV-containing PYGB and promotes the retention of 
PYGB in heart tissues 
(A) Western blot band intensities of PYGB in EVs from 200 µL of 
serum from mice pretreated with vehicle, MnP (2 mg/kg) or DRZ 
(200 mg/kg) 30 min before SAL or DOX treatment (B) Western blot 
band intensities of PYGB in heart tissues from mice pretreated with 
vehicle, MnP or DRZ (mean ± SD, n = 6-8, n = number of 250 l-
serum samples used for EV isolation, * p < 0.05 vs Saline, # p < 
0.05 vs control DOX). Adapted from Yarana et al. Clin Cancer Res. 
2018 Apr 1;24(7):1644-1653. 
EV-encapsulated GPs are sensitive indicators of DOX-induced tissue injury 
 Because EV release is a compensatory mechanism that the cell uses to 
remove toxic molecules before cell death occurs, EVs could be a sensitive 
biomarker for predicting tissue injury from chemotherapy. Here, we compared the 
sensitivity of EV-encapsulated GPs to the conventional tissue injury markers 
 
69 
 
such as cTnI for heart injury, ALT for liver injury, and CKMM for muscle injury. 
The data from western blotting showed clearly that the levels of EV_PYGB, 
EV_PYGM, and EV_PYGL were significantly increased in DOX-treated mice 
(Figure 2.16A-2.16D). We did not use any EV protein markers for normalization 
because the markers are uniquely expressed in specific subsets of EVs [150]. 
Since DOX_EVs and SAL_EVs were composed of different subsets of EVs as 
indicated by the size, there was no appropriate protein to normalize the values.  
Intriguingly, the elevation of EV-associated PYGB, PYGL, and PYGM after 
DOX treatment was proportionally higher than cTnI, ALT, and CKMM, 
respectively (Figure 2.16A-2.16G), suggesting that GPs are more sensitive than 
the conventional biomarkers to detect DOX-induced tissue injuries. Moreover, by 
measuring EV_PYGB by ELISA, we detected significant differences between 
SAL- and DOX-treated mice as early as 24 h post-treatment, whereas 
differences in cTnI were not detected until 72 h post-treatment (Figure 2.17A 
and 2.17B). These data suggest that EV_PYGB is better than the conventional 
serological markers at early detection of DOX-induced cardiac injury. 
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Figure 2.16 EV-associated glycogen phosphorylases are 
sensitive DOX-induced tissue injury markers 
(A) Western blots display PYGB, PYGM, and PYGL expression in 
EVs from mice treated with saline or DOX for 72 h. (B-D) Western 
blot band intensities for PYGB, PYGL, and PYGM levels (mean ± 
SD, n = 6, n = number of 250 l-serum samples used for EV 
isolation, * p < 0.05 vs SAL). (E-G) Serum levels of cTnI, ALT, and 
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CKMM measured by ELISA obtained from the SAL- and DOX-
treated mice in the same set of samples presented in A-D (mean ± 
SD, n = 6, n = number of mice, * p < 0.05 vs SAL). Adapted from 
Yarana et al. Clin Cancer Res. 2018 Apr 1;24(7):1644-1653. 
 
Figure 2.17 EV_PYGB can predict DOX-induced cardiotoxicity 
earlier than cTnI 
Comparison of cTnI (mean ± SD, n = 6, n = number of mice, * p < 
0.05 vs SAL at the same time point) (A) Comparison of EV_PYGB 
at different time points after SAL and DOX treatment (mean ± SD, n 
= 6, n = number of 250 l-serum samples used for EV isolation,  * p 
< 0.05 vs SAL at the same time point, # p < 0.05 vs DOX at 1 h, 24 
h and 48 h) (B). Adapted from Yarana et al. Clin Cancer Res. 2018 
Apr 1;24(7):1644-1653. 
Discussion 
Oxidative stress-mediated tissue injury is a major side effect of 
chemotherapy that can lead to multiple organ dysfunction. However, biomarkers 
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that are available to detect specific tissue injuries have not been linked to 
oxidative stress and are released only after cell death occurs. In this study, we 
exploited two properties of serum EVs that make them ideal early biomarkers for 
chemotherapy-induced tissue injury: lipid peroxidation, and tissue-specific 
proteins inside the EVs. Here, we demonstrated for the first time that EVs 
released from normal tissues affected by DOX have aberrant membrane 
morphology and higher protein-bound 4HNE levels. Proteomic analysis revealed 
that PYGB, PYGM, and PYGL are specific indicators for the tissue of origin of 
EVs released post-chemotherapy, which are brain/heart, skeletal muscle, and 
liver, respectively. Importantly, serum EVs are indicators of the level of tissue 
oxidative stress, as evidenced by the attenuation of 4HNE protein adduction, as 
well as the decreased release of EVs from heart tissue with enhanced 
antioxidant capacity. Thus, measurement of EV-associated protein-bound 4HNE 
and the tissue-specific cargo proteins may overcome the limitations encountered 
with the use of serum oxidative stress markers in terms of stability, extracellular 
oxidation, and specificity for the target tissue oxidative status.  
Lipid peroxidation products are one of the major effects of treatment with 
DOX. With TEM, we observed that the DOX_EV membrane was irregular. 
Changes associated with the DOX_EV membrane morphology might be a 
consequence of lipid peroxidation, which can influence the surface area, 
thickness, and permeability of the lipid membrane [63,151,152]. The larger size 
of DOX_EVs compared to SAL_EVs may result from a property of the lipid 
membrane, or the shift from exosome release to microvesicle release under 
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oxidative stress. The evidence for lipid peroxidation on the EV surface was 
strengthened by the observation of elevated protein-bound 4HNE after DOX 
treatment. The level of protein-bound 4HNE in EVs increased within 24 h after 
DOX treatment, which is consistent with our previous reports, in which 4HNE 
adduction accumulated in cardiac tissues as early as 3 h, peaking at 6 h, with a 
subsequent decline at 24 h [13,153]. The disappearance of protein-bound 4HNE 
from the tissue and its appearance in EVs at 24 h prompts speculation that EV 
release may provide a mechanism to remove oxidatively modified protein, which 
is highly toxic to cells.  
The increased levels of protein-bound 4HNE in circulating EVs suggest an 
oxidative stress-related mechanism in the tissues producing the EVs. This 
finding, coupled with the proteomic analysis, which identified a set of proteins 
with tissue-specific EVs, implicates tissue injury. The proteomic profiling revealed 
TfR1 and MHC-I as uniquely expressed proteins in SAL_EVs but not in 
DOX_EVs. TfR1 is a membrane protein for transferrin-iron complex uptake in 
erythrocyte precursors. This protein is released in the form of exosomes during 
erythrocyte maturation {American Cancer Society, 2014 #151}. The 
disappearance of TfR1 from DOX_EVs is consistent with the myelosuppressive 
effect of DOX, which peaks by day 3 post-treatment and is associated with a 
90% reduction of total bone marrow cells [154]. MHC-I, on the other hand, is 
required for selection of naïve CD8+ T lymphocytes, which occurs in the thymus 
and other immune-related tissues, and for presentation of intracellular peptide-
antigens to cytotoxic (CD8+) T lymphocytes [155]. Moreover, peripheral MHC-I is 
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also involved in the repopulation of CD8+ T cells outside the thymus [156]. 
Previous reports from our group showed that acute DOX treatment caused 
thymus atrophy and subsequent loss of T cell maturation in the thymus [157]. In 
the present study, loss of MHC-I from DOX_EVs suggests an interference with 
the maintenance of T cell survival in peripheral blood, potentiating the 
immunosuppressive effect of DOX on any adaptive immune response. In contrast 
to SAL_EVs, proteins uniquely expressed in DOX_EVs are related to the 
oxidative and metabolic stress response. Hp is an acute-phase protein, released 
predominantly from liver. Hp functions as an antioxidant by binding to extra-
corpuscular hemoglobin during hemolysis. This action impedes heme-iron 
exposure to an oxygenated environment, averting the Fenton reaction, which 
leads to ROS production [158].  
Metabolic alteration also occurs in many tissues after DOX treatment. 
Gene expression [159] and metabolomics [160] analyses of DOX-treated cardiac 
tissue show that myocardial metabolism switches from fatty acid oxidation to 
anaerobic glycolysis. Glycogenolysis provides alternative source of glucose 
derived from glycogen breakdown during stress conditions. Glycogenolysis is 
regulated by one of 3 isoforms of GP in a tissue-specific manner. The brain 
isoform, encoded by the PYGB gene, is enriched in heart and brain tissues. The 
muscle isoform, encoded by PYGM gene, and the liver isoform, encoded by 
PYGL gene, are enriched in skeletal muscle and liver, respectively [161]. The 
current study demonstrates that all three GP isoforms are expressed in 
DOX_EVs. Interestingly, PYGB, PYGM, and PYGL were depleted from heart, 
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skeletal muscle, and liver, respectively, after DOX treatment, suggesting that the 
EV-encapsulated PYGB, PYGM, and PYGL were released from those particular 
tissues. However, we did not observe a decrease of PYGB in the brain tissues of 
DOX-treated mice. Because DOX does not cross the blood-brain barrier, our 
data indicate that EV-associated GPs are released from the tissues that are 
directly affected by the drug. Therefore, the data suggest that EVs containing a 
specific GP may be an indicator of the injury of direct target tissues from DOX, 
specifically glycogenolysis dysfunction, which might be an early sign of tissue 
injury during chemotherapy. 
The strong association of EV release with oxidative stress was shown in 
the co-immunoprecipitation of 4HNE-adducted EVs with GP, suggesting that 
those EVs were released from tissues experiencing high oxidative stress. 
Moreover, mice with higher antioxidant capacity, such as MnSOD-
overexpressing mice or MnP-pretreated mice, released lesser amounts of EVs 
following DOX treatment. Furthermore, a clinically approved cardioprotective 
drug that has antioxidant effects, DRZ, also reduced the amount of EV release 
from heart tissue. However, the effect of DRZ on EV release was weaker than 
that of MnP, which might be explained by the stronger antioxidant effects of MnP 
over DRZ. This finding might warrant a clinical trial comparing cardioprotective 
effect of MnP vs. DRZ against DOX. Moreover, the relationship between 4HNE-
adducted EVs and the level of tissue oxidative stress can be utilized in 
personalized medicine, where we can use EVs to predict antioxidant capacity 
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against chemotherapy of individual patients and adjust the dose of chemotherapy 
to avoid normal tissue injury.  
Compared to conventional serum biomarkers, EV-associated GP can 
detect chemotherapy-induced tissue injury earlier, which would allow the initiation 
of preventive intervention to preserve normal tissue function before cell death 
occurs. However, because our study is based on normal mice without cancer, 
our result is only valid for predicting tissue injury in patients that no longer have 
tumors, such as long-term cancer survivors. In patients that still have tumors, EV-
associated GP may also be released from the tumor itself. Further studies in 
tumor-bearing mice should be performed to confirm this speculation. 
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CHAPTER THREE. OXIDIZED EXTRACELLULAR VESICLES ARE IMMUNE 
MODULATORS IN CHEMOTHERAPY-INDUCED NORMAL TISSUE INJURY. 
Overview 
DOX is known to cause oxidative stress and inflammation in heart tissue 
as well as in the systemic circulation. Extracellular vesicles (EVs) are released 
from cells during oxidative stress and send oxidized molecules into the circulation 
as a compensatory mechanism that prevents cellular proteotoxicity. Immune cells 
can sense oxidized molecules in EVs as molecular patterns associated with 
damage, which leads to immune activation. By using a mouse model of DOX -
induced tissue injury, we previously found that EVs are released from target 
tissues of DOX-treated animals, including the heart and the liver. Here, we 
compared the effects of EVs from cardiomyocytes and hepatocytes on changes 
in macrophage phenotype (phenotype switching) in a cell culture system. EVs 
from H9c2 cardiomyocytes (H9c2 EVs) and FL83b hepatocytes (FL83b EVs) 
have different levels of protein-bound 4-hydroxynonenal and, thus, different 
immunogenic effects on macrophages. H9c2 EVs but not FL82b EVs induce 
macrophages to exhibit both pro-inflammatory and anti-inflammatory phenotypes, 
which are mediated by NFκB activation and upregulation of anti-oxidant enzymes 
via Nrf2 activation. This macrophage phenotype was previously described as the 
Mox macrophage, which is expressed when the macrophages are challenged 
with oxidized phospholipids. DOX enhances the effects of H9c2 EVs but not 
FL83b EVs. Mechanistically, the different functions of H9c2 EVs and FL83b EVs 
on macrophage phenotype switching are due to their different effects on 
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Thioredoxin 1, which is a redox- sensitive protein that regulates the immune 
response under oxidative stress. Our findings shed light on the role of EVs as a 
redox active mediator of immune response during chemotherapy. 
Introduction 
DOX is one of the most potent chemotherapeutic agents but its efficacy is 
limited by severe side effects to normal tissues. The toxicity of DOX is not limited 
to the acute phase, when the drug is present in the body, but it lasts for many 
decades after the treatment cessation. The reason for that is because of the 
continued propagation of oxidative stress from oxidized toxic molecules. To 
maintain cellular homeostasis, cells have developed a variety of mechanisms to 
remove oxidized toxic molecules including ubiquitin-proteosome degradation, 
autophagy and mitophagy. However, under DOX-induced severe oxidative 
stress, these mechanisms are compromised [34,88]. Thus, the cells are forced to 
remove those toxic molecules by alternative pathways. 
Extracellular vesicles (EVs) are small membrane-encapsulated structures 
that are released from the cell under normal and pathological conditions. Several 
protein machineries in EV formation are utilized for in oxidized molecule sorting 
but instead of being degraded inside the cells, those molecules are exported out 
of the cells and mediate intercellular communication. Accumulating evidence has 
revealed the important role of EVs in the context of oxidative stress. Many of 
them are related to the transfer of damage associated molecular patterns 
(DAMPs) to activate immune cells [71,74-76]  
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Macrophages are mononuclear phagocytic cells that mediate the innate 
immune response by recognizing microbial and endogenous danger- signaling 
molecules [162]. Upon sensing environmental stimuli, macrophages can be 
polarized into different phenotypes with distinct sets of gene expression, cytokine 
release, cellular metabolism, and biological functions. Generally, macrophage 
polarization is classified into two phenotypes: pro-inflammatory (M1) and anti-
inflammatory (M2) macrophages. M1 macrophages express and release pro-
inflammatory cytokines including TNF alpha, IL-1 beta, IL-6, and generate 
reactive oxygen or reactive nitrogen species in order to eliminate microbes as 
well as cell debris. In contrast, M2 macrophages release anti-inflammatory 
cytokines such as IL-10, and TGF beta that inhibit the effect of M1 thus limiting 
tissue inflammation and promote tissue repair. In physiologic conditions, M1 and 
M2 activities are strictly regulated. Severe pro-inflammatory immune responses 
can lead to a secondary cytotoxicity and tissue destruction while excessive anti-
inflammatory responses can lead to tissue fibrosis. Tissue injury induced by DOX 
is not limited to the direct effects on the target tissues, but also involves the 
indirect effects from inflammation initiated by the innate immune response to the 
endogenous danger signals [101,163]. Moreover, the inflammatory cytokines 
generated locally in the tissues can enter the circulation and have an effect on 
distant organs.  
Previously, we identified the heart and liver as the major tissues that 
contribute to circulating EVs after DOX treatment. However, the function of EVs 
released from these two organs that have different levels of oxidative stress has 
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not yet been investigated. The cardiomyocyte is the most sensitive cell type for 
DOX-induced oxidative stress [164] making cardiomyopathy the most concerning 
side effect in cancer patients receiving DOX, as well as other chemotherapeutic 
agents that involve reactive oxygen species (ROS) generation. Unlike cardiac 
dysfunction, liver dysfunction is rarely observed in DOX-treated patients [165]. 
The reason for this might be due to an enrichment in antioxidant enzymes [166] 
and drug transporters in the liver [167].  
Here, we demonstrate that cardiomyocytes and hepatocytes release EVs 
with different oxidized protein levels and have differential effects on 
macrophages Thioredoxin 1 (TRX1), a redox regulator, regulates macrophage 
polarization in response to EVs by controlling the redox sensitive transcription 
factors NFκB and Nrf-2. The findings of this study provide insight into the 
intercellular communication between injured cells and macrophages coordinated 
by EVs in response to DOX treatment and provide a new target for treatment of 
DOX-induced inflammation. 
Materials and Methods 
Cell Culture and Treatment 
H9c2 embryonic rat normal cardiomyocytes, FL83b fetal mouse normal 
hepatocytes, Raw264.7 Abelson murine leukemia virus transformed mouse 
macrophage, and NR8383 rat alveolar macrophage cell lines were obtained from 
the American Type Culture Collection (Manassas, VA). H9c2 cells were 
maintained in DMEM low glucose supplemented with 10% FBS, 1% 
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penicillin/streptomycin, 1 mM pyruvate, 25 mM HEPES, 2 mM glutamine, 1% 
non-essential amino acids. FL83b cells were maintained in F12 medium 
supplemented with 10% FBS and 1% penicillin/streptomycin. RAW264.7 cells 
were maintained in DMEM high glucose supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. NR8383 cells were maintained in 
Ham’s F12K medium supplemented with 15% heat inactivated FBS, 2 mM L-
glutamine, and 1.5 g/L sodium bicarbonate. The absence of mycoplasma 
contamination was confirmed in all cell lines.  
For macrophage activation, RAW264.7 cells were seeded at a density of 
5x105 cells/well in 6 well-plate overnight and incubated with FBS free media 
supplemented with 20 µg of H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, FL83b 
DOXEV, or an equal volume of PBS as a vehicle for 24 h. The conditioned media 
were then collected and were frozen at -80º C until used. 
Cell Viability Test 
The sensitivity to DOX toxicity of H9c2 and FL83b cells was measured 
with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
(MTT) reduction assay. This assay relies on electron transfer from NADH and 
NADPH to MTT, which is achieved by oxidoreductase enzyme activity in viable 
cells [168]. The final product is the insoluble purple colored formazan. In this 
experiment, H9c2 or FL83b cells were seeded in 96-well plates at the density 
1000 cells/100 µl/well. The next day the cells were exposed to 0.5 μM of DOX for 
24 hours. Cells were then washed with PBS and 30 μl of MTT solution (5 mg/ml 
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in PBS) was added to each well and incubated for 1 hour. Then, 70 μl of 50% 
DMSO and 50% SDS was added to solubilize the formazan crystals. Absorbance 
was determined at 540 nm by SpectraMax Plus 384 microplate reader (Molecular 
Devices, San Jose, CA). DOX cytotoxicity was expressed as the percent viability 
in treated cells relative to the non-treated control. 
EV Isolation and Quantitation 
H9c2 and FL83b were treated or not treated with 0.5 μM DOX in 20 ml 
growing media for 1 h followed by washing with 3 x 10 ml PBS. The media was 
changed to EV-free growing media and incubated for 48 hours before the 
conditioned media collection. The conditioned media were filtered through 0.8 μm 
syringe filters to exclude vesicles larger than 0.8 μm, which are typically the 
apoptotic bodies. The filtered conditioned media were stored at -80 ºC until use. 
EVs were isolated by an affinity-based membrane method using exoEasy 
maxi kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
All types of EVs including exosomes, microvesicles, and apoptotic bodies were 
bound to the spin column and eluted to obtain EV products. The conditioned 
media were thawed at room temperature and 32 ml of the media were then 
mixed 1:1 with buffer XBP and applied onto the affinity spin column allowing EV 
binding to the membrane. After centrifugation at 500 x g for 1 min, the flow-
through was discarded. XWP buffer was added to the column and centifuged at 
5000 x g for 5 min to wash off contaminating proteins and residual buffer. Buffer 
XE was then applied onto the membrane and centrifuged at 500 x g, 5 min to 
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elute EV from the column. The eluated was applied to the column again and 
centrifuged at 5000 x g, 5 min. Since XE buffer contains primarily inorganic salts 
that are toxic to cells, buffer exchange with PBS were performed using 3 kDa 
Amicon Ultra-15 Centrifugal Filter units (Millipore Sigma, Burlington, MA). The 
amount of EVs was evaluated by bicinchoninic acid assay (Thermo Fisher 
Scientific, Waltham, MA). 
4HNE Adducted Protein Measurement 
EVs from H9c2 non-treated (H9c2 NTEV), H9c2 DOX-treated (H9c2 
DOXEV), FL83b non-treated (FL83b NTEV), and FL83b DOX-treated (FL83b 
DOXEV) were lysed with radioimmunoprecipitation assay (RIPA) buffer and 
mixed with an equal volume of Laemmli buffer. Equivalent protein samples (250 
ng) were then loaded on nitrocellulose membrane using Bio-Dot SF microfiltration 
apparatus (Bio-Rad). The membranes were allowed to air dry overnight. The next 
day, the membranes were blocked with blocking buffer for 2 h followed by 
incubation with anti-4HNE antibody (1:5000 dilution) for 1 h on an orbital shaker. 
After washing with TBST three times, the membranes were incubated with 
IRDye® 800CW donkey anti-rabbit (1:15,000 dilution) for 1 h. Then, the 
membranes were washed and allowed to air dry. The 4HNE-adducted protein 
bands were visualized using Odyssey scanner (LI-COR). 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
For macrophage activation, RAW264.7 cells were seeded at the density of 
1x106 cells/well in 6 well-plate overnight and were incubated with 20 µg of EVs 
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from non-treated H9c2 cells, DOX-treated H9c2 cells, non-treated FL83b cells, 
and DOX-treated FL83b cells for 6 or 24 hours. RNA was isolated from the cells 
using the MagNA Pure Compact RNA Isolation kit (Roche, Risch-Rotkreuz, 
Switzerland). The RNA integrity was evaluated using the Agilent 2100 
Bioanalyzer System (Santa Clara, CA). The mRNAs were reverse transcribed to 
cDNA using the first strand cDNA Synthesis Kit (Roche). The Nanodrop 
Spectrophotometer (Thermo Fisher Scientific) was used to measure cDNA 
concentration. Quantitative real-time PCR was performed using a LightCycler 
480 Real-Time PCR System (Roche) with gene-specific primers. All primers were 
purchased from Invitrogen. Primer sequences for mouse genes were as follows:  
Mouse Tnf 5’-CCTGTAGCCCACGTCGTAGC-3’ (Forward) and 5’-
AGCAATGACTCCAAAGTAGACC-3’ (Reverse);  
Mouse Il1b 5’-GCACTACAGGCTCCGAGATGAAC-3’ (Forward) and 5’-
TTGTCGTTGCTTGGTTCTCCTTGT-3’ (Reverse);  
Mouse IL-6 5’- GACAAAGCCAGAGTCCTTCAGAGAG-3’ (Forward) and 5’- 
CTAGGTTTGCCGAGTAGATCTC-3’ (Reverse);  
Mouse iNOS 5’-TTTGCTTCCATGCTAATGCGAAAG-3’ (Forward) and 5’-
GCTCTGTTGAGGTCTAAAGGCTCCG-3’ (Reverse);  
Mouse IL-10 5’-ATTTGAATTCCCTGGGTGAGAAG-3’ (Forward) and 5′-
CACAGGGGAGAAATCGATGACA-3′ (Reverse); 
Mouse HO-1 5′-GGTGATGGCTTCCTTGTACC-3′ (Forward) and 5′-
GGTGATGGCTTCCTTGTACC-3′ (Reverse);  
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Mouse PRDX1 5’-ACACCCAAGAAACAAGGAGGATT-3’ (Forward) and 5’-
CAACGGGAAGATCGTTTATTGTTA-3’ (Reverse); 
Mouse Actb 5’-TGGAATCCTGTGGCATCCATGAAAC-3’ (Forward) 5’-
TAAAACGCAGCTCAGTAACAGTCCG-3’ (Reverse); 
Rat Il1b 5’- GCAATGGTCGGGACATAGTT-3’ (Forward) 5’- 
AGACCTGACTTGGCAGAGGA-3’ (Reverse); 
Rat Nos2: 5’-TAGTCAACTACAAGCCCCACG-3’ (Forward) 5′-
GTGAGGAACTGGGGGAAACC-3′ (Reverse); 
Rat Il10 5’GTTGCCAAGCCTTGTCAGAAA-3’ (Forward) 5’- 
TTTCTGGGCCATGGTTCTCT-3’ (Reverse); 
Rat Actb 5’-AGGCATCCTCACCCTGAAGTA-3’ (Forward) 5’- 
CACACGCAGCTCATTGTAGA-3’ (Reverse). 
The PCR cycles were as follows: initial denaturation 10 min at 95ºC, 45 
cycles of 15 sec at 95ºC, 30 sec at 60 ºC, and 30 sec at 72ºC. 
Multiplex Cytokines Array 
V-PLEX mouse cytokine immunoassay kit (Meso Scale Diagnostics, 
Rockville, MD) was used to measure TNF alpha, IL-1 beta, IL-6, and IL-10 (Meso 
Scale Diagnostics, Rockville, MD). Mouse TGF-beta 1 DuoSet ELISA (R&D 
systems, Minneapolis, MN) was used to measure TGF beta 1. All assays were 
performed according to the manufacturer’s protocol. All standards and samples 
were measured in duplicate or triplicate. 
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Nitric Oxide (NO) Measurement 
RAW264.7 cells were treated with FBS-free DMEM without phenol red, 
and supplemented with 20 µg of EVs or an equal volume of the vehicle control. 
The conditioned media were collected at 24 hours post-treatment. Since NO is 
unstable and completely oxidized in biological fluid, we measured the 
accumulation of the stable oxidized products of NO, nitrite and nitrate, in the 
conditioned media using Nitrate/Nitrite colorimetric assay kit (Cayman, Ann 
Arbor, MI). Briefly, the conditioned media was incubated with nitrate reductase to 
convert nitrate to nitrite. Then, Griess reagents were added to react with total 
nitrite and generate deep purple azo compound. The change in color was 
evaluated by reading the absorbance at 540 nm using a microplate reader 
(Molecular Device, San Jose, CA). The concentration of nitrate/nitrite in samples 
was calculated from a standard curve generated using known concentration of 
nitrate. 
Mitochondrial and Glycolysis Stress Test 
RAW264.7 cells were seeded into a 96 well plate (Seahorse Bioscience, 
North Billerica, MA) at the density of 20,000 cells/well for both the mitochondrial 
and glycolysis stress tests. The next day, the cells were treated with 20 µg/ml of 
EVs or an equal volume of PBS for 24 hours prior to the test. For the 
mitochondrial stress test, oxygen consumption rate (OCR) was determined using 
the Seahorse XF-96 analyzer (Seahorse Bioscience). OCR was measured at 
baseline (Basal OCR) followed by the sequential addition of oligomycin (1 µM) to 
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inhibit ATP synthase, FCCP (1 µM) uncoupler to permeabilize the inner 
mitochondrial membrane and promote maximum electron flow, or rotenone (1 
µM) / antimycin (1 µM) to inhibit complex I and complex III, respectively. ATP-
linked OCR was calculated by subtracting the OCR after oligomycin treatment 
from the basal OCR. The spare respiratory capacity was calculated by 
subtracting the basal OCR from the maximal OCR after FCCP treatment. For the 
glycolysis stress test, the extracellular acidification rate (ECAR) was determined 
with the Seahorse XF-96 analyzer. ECAR was measured at baseline followed by 
the sequential addition of glucose (10 mM), Oligomycin (1 µM), and 2-
deoxyglucose (50 mM). Basal glycolysis was calculated by subtracting the ECAR 
measurement post-2-deoxyglucose addition from the ECAR measurement post-
Glucose addition. The glycolytic reserve capacity was calculated by subtracting 
the post-Oligomycin measurement from the post-Glucose measurement. 
Western Blot Analysis 
For EVs western blots, EVs suspension in PBS (0.5 µg/µl) was lysed with 
RIPA buffer containing protease inhibitor and sonicated for 3 x 30 sec using a 
water sonicator. For western blots of macrophage proteins, cells were lysed by 
incubating with RIPA buffer containing protease inhibitor on ice for 30 min. 
Protein concentrations were determined using bicinchoninic acid assay. SDS 
polyacrylamide gels (8-15%) were loaded with 50 µg of lysed EVs or 40 µg of 
whole cell lysates and electrophoresis was performed at 100 V for 2 h. The 
proteins were transferred onto nitrocellulose membranes. After blocking with 
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 h, the 
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membranes were incubated overnight with primary antibodies  at 4ºC. The 
following primary antibodies were used: anti-Alix, anti-CD81, anti-caspase-1, 
anti-HDAC1, anti-Lamin A/C (Santa Cruz Biotechnology, Dallas, TX), anti-NLRP3 
(MyBioSource, San Diego, CA), anti-IL-1 beta (PromoCell GmbH, Heidelberg, 
Germany), anti-beta actin (Sigma-Aldrich, St. Louis, MO), anti-MnSOD (Upstate 
Biotechnology, Waltham, MA), The membranes were washed three times with 
TBST buffer and were incubated with IRDye 800 CW donkey anti-goat for anti-
Alix, donkey anti-rabbit for anti-CD81, anti-NLRP3, anti-caspase-1, anti-IL-1 beta, 
and anti-MnSOD, or goat anti-mouse for beta-actin, anti-HDAC1, and anti-Lamin 
A/C for 1 h at room temperature. After washing three times, the membranes were 
air dried and the protein bands were visualized using the Odyssey scanner (LI-
COR). 
NFκB and Nrf-2 DNA Binding Activity 
To measure NFκB and Nrf-2 transcription factor activity, DNA binding 
ELISA was performed using TransAM NF-κB and Nrf-2 kit (Active motif, 
Carlsbad, CA) according to the manufacturer’s protocol. Breifly, nuclei from 
RAW264.7 cells were extracted by nuclear extract kit (Active motif). Then, the 
nuclear extract was added onto the oligonucleotide-coated well and incubate for 
1 hour. After the washing step, the primary antibody for NF-κB (p65) or Nrf-2 was 
added and incubated for 1 hour. Then, the plates were washed and incubated 
with the HRP-conjugated secondary antibody for 1 h. The color was developed 
by the developing solution and the absorbance was read at 450 nm. 
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Thioredoxin 1 Redox Western 
Reduced and oxidized forms of thioredoxin 1 (TRX1) in nuclear and 
cytoplasmic portions of RAW264.7 cells treated with EVs were detected as 
described previously [169-171] After incubation of EVs for 24 hours, the cells 
were washed with ice-cold PBS and lyse with hypotonic solution supplemented 
with protease inhibitor and 50 mM iodoacetic acid (IAA). The lysate was 
centrifuged at 16,100 g for 2 min and the supernatant was collected as the 
cytoplasmic fraction. The nuclear pellet was lysed with G-lysis buffer 
supplemented with protease inhibitor and IAA. Iodoacetic acid (IAA) was used to 
modify the thiol group resulting in one negative charge addition per one 
modification. Microspin G-25 columns were used to remove excessive IAA. After 
the derivatization, TRX1 redox forms were separated by charge using native 
polyacrylamide gel electrophoresis and were detected using anti-TRX1 antibody 
(AdipoGen Life Sciences, San Diego, CA) as a primary antibody and IRDye® 
800CW donkey anti-Rabbit as a secondary antibody. The protein bands were 
visulized using Odyssey scanner (LI-COR, Lincoln, NE). The band intensities 
were assessed using Image Studio 5.x software (LI-COR) 
Statistical Analysis 
Results are presented as the mean ± standard deviation (SD) or standard 
error of the mean (SEM) as indicated in the figure legend.  Analysis of variance 
(ANOVA) was used for comparison of study endpoints including 4HNE slot blot, 
western blot, and Trx1 redox western, EVs, and other parameters in the 
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macrophages from cardiomyocytes and hepatocytes.  Pairwise comparisons 
were performed from the ANOVA model between vehicle versus treated and 
differences between H9c2 NTEV vs H9c2 DOXEV, FL83b NTEV vs FL83b 
DOXEV, H9c2 NTEV vs FL83b NTEV, and H9c2 NTEV vs FL83b 
DOXEV.  Adjusted p-values due to multiple testing were calculated using the 
Holm’s method.  A value of P<0.05 was considered significant. The SAS system 
version 9.4 was used for data analysis. Excel and GraphPad Prism were used for 
graphing.  
 
Results 
DOX induced cardiomyocytes—but not hepatocytes—release EVs with 
higher levels of protein-bound 4HNE.  
By measuring cell viability after 24 h of DOX treatment, the result shows 
that the viability of H9c2 cells decreased by 13 % while FL83b cell viability was 
similar to the non-treated control. These data indicate that H9c2 cells are more 
sensitive to DOX than FL83b cells (Figure 3.1A). The quantity of EVs, as 
indicated by the level of EV protein, reveals that H9c2 and FL83b cells release 
equal amounts of EVs per equal number of cells under normal conditions. DOX 
induced at least a 4-fold increase in EV release from both H9c2 and FL83b cells 
(Figure 3.1B). However, with an equal amount of EV protein, EVs from H9c2 
cells had more protein-bound 4HNE than EVs from hepatocytes. Moreover, 
comparisons between DOX-treated EVs (DOXEV) and non-treated EVs (NTEV) 
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showed that the H9c2 DOXEV contained more 4HNE adducted proteins than the 
H9c2 NTEV. However, there was no difference between FL83b DOXEV and 
FL83b NTEV. (Figure 3.1C). These data suggest that DOX induces 
cardiomyocytes but not hepatocytes to release EVs with higher level of oxidized 
proteins.  
 
Figure 3.1 Comparison of DOX toxicity, the level of EVs and 
the level of 4HNE protein adduction in the EVs released from 
cardiomyocytes and hepatocytes 
 (A) Percentage of surviving H9c2 cells and FL83b cells after 0.5 
µM DOX treatment for 24 h (green bars) compared to non-treated 
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control (black bars). * p < 0.05 vs non-treated cells (B) Amount of 
EVs released from one million cells in non-treated H9c2, DOX-
treated H9c2, non-treated FL83b, or DOX-treated FL83b cells. * p < 
0.05 vs non-treated cells (C). Western blots of EVs markers: Alix 
and CD81 in EVs derived from non-treated H9c2 (H9c2 NTEV), 
DOX-treated H9c2 (H9c2 DOXEV), non-treated FL83b (FL83b 
NTEV), or DOX-treated FL83b (FL83b DOXEV). (D) The levels of 
4HNE protein adduction in H9c2 NTEV, H9c2 DOXEV, FL83b 
NTEV, or FL83b DOXEV. Data represent the mean of band 
intensities relative to H9c2 NTEV ± SD of 5 independent 
experiments * p < 0.05 vs H9c2 NTEV. 
 
Differential effects of H9c2 EVs and FL83b EVs on M1 and M2 polarization.  
To investigate the effect of EVs on macrophage polarization, RAW264.7 cells 
were treated with EVs and gene expression of M1 markers including TNF alpha, 
IL-1 beta, IL-6 and iNOS, as well as M2 marker IL-10 were measured at 6 h and 
24 h after treatment. To select the appropriate dose of EVs for the whole study, 
RAW264.7 cells were treated with various doses of H9c2 NTEV, H9c2 DOXEV, 
FL83b NTEV, and FL83b DOXEV and TNF alpha gene expression was 
measured. The result shows that both H9c2 NTEV and H9c2 DOXEV 
upregulated TNF alpha in dose-dependent manner. However, the significant 
difference between H9c2 NTEV and H9c2 DOXEV were observed at 20 µg 
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treatment (Supplementary figure 3.1A). In contrast, with the similar various 
concentration of EV treatment, neither FL83b NTEV nor FL83b DOXEV induced 
TNF alpha gene expression (Supplementary figure 3.1B).  
 
Supplementary figure 3.1  Comparison of the effect of 
various doses of EVs on macrophage TNF alpha gene 
expression  
(A) TNF alpha mRNA levels in RAW264.7 cells treated with 0, 10, 
20, and 40 µg of H9c2 NTEV (blue) or H9c2 DOXEV (red), Data 
represent the mean ± SD of 3 independent experiments * p < 0.05 
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vs 0 µg, $ p < 0.05 vs 10 µg, # p < 0.05 vs 20 µg, ¶ p < 0.05 vs 
H9c2 NTEV. (B) TNF alpha mRNA levels in RAW264.7 cells 
treated with 0, 20, and 40 µg of FL83b NTEV (blue) or FL83b 
DOXEV (red) Data represent the mean ± SD of 3 independent 
experiments 
By treatment with 20 µg of EVs, the data show that H9c2 EV but not 
FL83b EV induce M1 and M2 polarization as evidenced by the increase in both 
M1 and M2 markers. DOX treatment promoted both M1 and M2 
immunostimulatory effects in H9c2 EVs but not in FL83b EVs (Figure 3.2A-3.2J).  
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Figure 3.2 Cardiomyocyte-derived EVs but not hepatocyte-
derived EVs promote both M1 and M2 macrophage gene 
expression. Cardiomyocyte EV levels was potentiated by DOX 
treatment. 
(A-H) Graphs demonstrate the fold change of M1 macrophage 
gene expression for TNF alpha (A, B), IL-6 (C, D), IL-1 beta (E, F), 
and iNOS (G, H) in RAW264.7 cells with 6 and 24 hour incubation 
of EVs from non-treated and DOX-treated H9c2 cells, and non-
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treated and DOX-treated FL83b cells. (I-J) Fold change of M2 gene 
IL-10 in RAW264.7 macrophages with 6 and 24 hour incubation of 
EVs from H9c2 non-treated, H9c2 DOX-treated, FL83b non-treated 
and FL83b DOX-treated. Data represent the mean ± SD of 3-5 
independent experiments * p < 0.05 vs vehicle control, # p < 0.05 
vs H9c2 NTEV 
The M1 and M2 effects of EVs on macrophage gene expression were 
confirmed by the increase in pro- and anti-inflammatory cytokines release into 
the conditioned media at 24 h post EV treatment (Figure 3.3A-3.3E), as well as 
by the increase in nitric oxide (NO) production (Figure 3.3F). The NO generation 
is specific to NOS expression because it is suppressible by N(G)-Nitro-L-arginine 
methyl ester (L-NAME), which is a competitive inhibitor of NOS.  
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Figure 3.3 Cardiomyocyte-derived EVs but not hepatocyte-derived 
EVs promote both pro-inflammatory and anti-inflammatory cytokine 
release as well as nitric oxide production from macrophage. The 
effect was potentiated by DOX treatment 
(A-C) Levels of pro-inflammatory cytokines TNF alpha, IL-1 beta, 
IL-6 in RAW264.7 cells treated for 24 hours with vehicle, EVs from 
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H9c2 non-treated EVs (H9c2 NTEV), H9c2 DOX-treated EVs (H9c2 
DOXEV), FL83b non-treated EVs (FL83b NTEV) and FL83b DOX-
treated EVs (FL83b DOXEV). (D-E) Levels of anti-inflammatory 
cytokines; IL-10 and TGF beta in RAW264.7 cells treated for 24 
hours with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and 
FL83b DOXEV. (F) Level of Nitrite/Nitrate as a parameter of NO 
production in RAW264.7 cell treated with vehicle, H9c2 NTEV, 
H9c2 DOXEV, FL83b NTEV, and FL83b DOXEV. L-NAME was 
used as a negative control as well as the inhibitor of H9c2 EV effect 
on NO production. L-NAME = N(G)-Nitro-L-arginine methyl ester, 
Data represent the mean ± SEM of 4 independent experiments * p 
< 0.05 vs vehicle control, # p < 0.05 vs H9c2 NTEV 
The immunostimulatory effect of H9c2 EVs was not due to species 
differences between rat cardiomyocytes and mouse macrophages as we 
observed similar results with NR8383 rat macrophages (Supplementary figure 
3.2). 
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Supplementary figure 3.2 Gene expression of NR8383 rat 
macrophages after EV treatment for 24 h 
(A) Bar graphs represents fold change of IL-1β, iNOS (B) and IL-10 
(C) gene expression measured by RT-PCR of macrophage treated 
with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and FL83b 
DOXEV. Data represent the mean ± SD of 3 independent 
experiments * p < 0.05 vs vehicle, # p < 0.05 vs H9c2 NTEV 
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Differential effects of H9c2 EVs and FL83b EVs on macrophage 
metabolism.  
M1 and M2 polarizations are supported by the metabolic pathways that 
macrophages use to produce energy [172]. Upon M1 activation, aerobic 
glycolysis is induced due to the ineffective enzymes in the Kreb’s cycle. On the 
other hand, M2 macrophages utilize mitochondrial oxidative phosphorylation 
(OXPHOS) to make ATP, and the intermediates from OXPHOS will help with 
tissue repair process [173]. Here, we observed that EVs induce the metabolic 
shifts in macrophages. Data from the mitochondrial stress and glycolytic stress 
tests show that EVs from DOX-treated H9c2 cells significantly suppressed basal 
OCR (Figure 3.4A and 3.4B) and enhanced glycolysis of macrophages (Figure 
3.5A and 3.5B), which is in support of the metabolic process expected for M1 
polarization. EVs from non-treated H9c2 cells also suppressed basal OCR and 
increased glycolysis but the levels did not reach statistical significance. However, 
EVs from both non-treated and DOX-treated H9c2 cells have no effect on 
glycolytic reserved capacity (Figure 3.5C). In contrast, EVs from FL83b did not 
have any effects on basal OCR, glycolysis, and glycolytic reserved (Figure 3.4A-
3.4B, 3.5A-3.5C) but they induced higher mitochondrial spare respiratory 
capacity (Figure 3.4C). These data suggest that EVs from hepatocytes did not 
induce either M1 or M2 polarization but they do enhance mitochondrial 
metabolism under stress conditions.  
 
101 
 
 
 
Figure 3.4 Differential effects of H9c2_EVs and FL83b_EVs 
on mitochondrial respiration  
(A) Kinetic graph of OCR at baseline and after oligomycin, FCCP, 
and rotenone/antimycin treatment of macrophages incubated with 
vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and FL83b 
DOXEV. (B) Bar graph represents the average of basal OCR 
calculated from graph A (C) Bar graph represents the average of 
Spare Respiratory Capacity calculated from graph A. Data 
represent the mean ± SEM of 3 independent experiments * p < 0.05 
vs vehicle 
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Figure 3.5 Differential effects of H9c2_EVs and FL83b_EVs 
on glycolysis  
(A) Kinetic graph of ECAR at baseline and after glucose, 
oligomycin, and rotenone/antimycin treatment of macrophages 
incubated with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, 
and FL83b DOXEV. (B) Bar graph represents the average of basal 
glycolysis calculated from graph A (C) Bar graph represents the 
average of Glycolytic reserve calculated from graph A. Data 
represent the mean ± SEM of 3 independent experiments * p < 0.05 
vs vehicle 
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Differential effects of H9c2 EVs and FL83b EVs on NFκB and Nrf-2 
transcription activity. 
Macrophage polarization is known to be regulated by redox signaling. 
NFκB and Nrf-2 are two interconnected redox sensitive transcription factors that 
control opposite immune responses during oxidative stress [174]. NFκB 
activation leads to the upregulation of pro-inflammatory target genes such as 
TNF alpha, IL-1 beta, IL-6 and chemokines. On the contrary, Nrf-2 activation 
upregulates anti-oxidant genes, which remove ROS and prevent inflammation 
[121]. Nrf-2 also has anti-inflammatory effect independent of ROS detoxification. 
Nrf-2 can directly suppress inflammation by binding to the promotor region of pro-
inflammatory cytokine genes such as IL-6 and IL-1 beta and inhibit RNA 
polymerase II recruitment to the transcription site [122]. By measuring the DNA 
binding activity of NFκB and Nrf2 in RAW264.7 macrophages treated with EVs, 
we found that H9c2 EVs but not FL83b EVs induced NFκB and Nrf-2 DNA 
binding activity. Similar to the gene expression results, DOX potentiated the 
effect of H9c2 EVs on NFκB and Nrf-2 activation but had no effect on FL83b EVs 
(Figure 3.6A and 3.6B). The activation of Nrf-2 was confirmed by upregulation of 
antioxidant gene expression, peroxiredoxin 1 (PRDX1) and heme oxygenase 1 
(HO-1) (Figure 3.6C and 3.6D).  
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Figure 3.6 Cardiomyocyte-derived EVs but not hepatocyte-
derived EVs enhanced NFκB and Nrf-2 transcription factor 
activity. The effect was potentiated by DOX.  
(A) NFkB DNA binding activity and (B) Nrf2 DNA binding activity in 
macrophages treated with vehicle, H9c2 NTEV, H9c2 DOXEV, 
FL83b NTEV, and FL83b DOXEV. (C, D) Fold change of anti-
oxidant gene expression; PRDX1 (C) and HO-1 (D) after 24 hour 
treatment of RAW264.7 cells with vehicle, H9c2 NTEV, H9c2 
DOXEV, FL83b NTEV, and FL83b DOXEV. Data represent the 
mean ± SD of 3 independent experiments* p < 0.05 vs vehicle, # p 
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< 0.05 vs H9c2 NTEV, PRDX1 = peroxyredoxin1, HO-1 = heme 
oxygenase-1 
Differential effects of H9c2 EVs and FL83b EVs on NLRP3 inflammasomes. 
The inflammasome is an intracellular complex that mediates maturation and 
re lease  o f IL -1  be ta  and  IL -18 fo r the  innate  im m une response. The 
inflammasome complex is composed of a nucleotide-binding oligomerization 
domain-like receptor containing protein (NLRP), apoptosis-associated speck like 
protein containing caspase recruitment domain (ASC), and inactive IL-1 
converting enzyme called pro-caspase-1 [175]. NLRP is a pattern recognition 
receptor that can sense pathogen-associated molecular patterns (PAMPs) 
present in exogenous microorganisms or damage-associated molecular patterns 
(DAMPs) formed by endogenous damaged cells. NLRP3 is the most 
characterized NLRP. NLRP3 activation requires both a priming signal to induce 
gene expression of NLRP3 itself, pro-IL-1 beta and pro-IL-18 via enhancing 
N F κB  tra n sc rip tio n  ac tiv ity , as well as an activation signal from PAMPs or 
DAMPs to induce inflammasome complex formation [176,177]. Once the 
complex is formed, pro-caspase 1 is converted to active caspase-1, which further 
cleaves pro-IL 1 beta and IL-18 into their mature active forms [178].  
Because we found that IL-1 beta release was induced by H9c2 EVs and 
potentiated by DOX, we investigated if the release of IL-1 beta is due to 
inflammasome activation. Western blots of inflammasome components in 
RAW264.7 cells treated with EVs shows that only H9c2 EVs but not FL83b EVs 
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activate NLRP3 inflammasomes as evidenced by an increase in NLRP3, pro-
caspase 1, cleaved caspase-1, and cleaved IL-1 beta. Comparing between H9c2 
NTEV and H9c2 DOXEV, DOXEV induced inflammasome activation slightly 
more than NTEV (Figure 3.7).  
 
Figure 3.7 NLRP3 inflammasome was activated by 
cardiomyocyte- but not hepatocyte-derived EV treatment. DOX 
enhance the effect of cardiomyocyte EVs on inflammasome 
activation.  
(A) Western blot analysis from whole cell lysates of RAW264.7 
macrophage treated with vehicle, H9c2 NTEV, H9c2 DOXEV, 
FL83b NTEV, and FL83b DOXEV using an anti-NLRP3, an anti-
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caspase-1 or an anti-IL-1 beta antibody. Βeta-actin was used as 
loading control. (B-D) Bar graphs represent the average of band 
intensities of NLRP3, Caspase-1, and IL-1 beta relative to Actin ± 
SD of 3 independent experiments * p < 0.05 vs vehicle, # p < 0.05 
vs H9c2 NTEV 
Differential effects of H9c2_EVs and FL83b_EVs on reduced thioredoxin 1 
(TRX1).  
Because TRX1 is a cytosolic redox sensitive protein that can regulate both 
NFκB, Nrf-2, and NLRP3 inflammasomes, we further investigated the effect of 
EVs on TRX1 in cytoplasm and nuclear fraction of RAW264.7 macrophages in 
response to EVs treatment. The purity of cytoplasmic and nuclear fractions was 
verified by western blot (Figure 3.8A). Since EVs from cardiomyocytes and 
hepatocytes have different levels of protein-bound 4HNE, we hypothesized that 
those EVs might have differential effects on the TRX1 redox status, and cause 
distinct downstream inflammatory signaling. Our data support this hypothesis. 
The TRX1 redox western blots show that H9c2 NTEV-treated macrophages 
tended to have lower reduced TRX1 levels in the cytoplasm compared to the 
vehicle-treated control and H9c2 DO XEV treatm ent significantly depleted 
cytoplasmic reduced TRX1. In contrast, FL83b DOXEV significantly increased 
the levels of cytoplasmic reduced TRX1. Macrophages treated with FL83b NTEV 
also increased cytoplasmic reduced TRX1 but levels did not reach statistical 
significance (Figure 3.8B and 3.8D). In the nuclear compartment, only the 
 
108 
 
reduced isoform of TRX1 was detected and there is no significant change after 
EV treatment (Figure 3.8C and 3.8E). These data suggest that EVs primarily 
have an influence on the cytoplasmic TRX1 redox state rather than in the 
nucleus. The depletion of cytoplasmic reduced TRX1 in H9c2 EVs treated cells is 
c o n s is t e n t  w i t h  NFκB and inflammasome activation, which explains M1 
polarization. Low levels of reduced TRX1 is an indicator of cellular oxidative 
stress, which might activate Nrf-2 as a defensive response. TRX1 also plays a 
crucial role in protein-protein interaction. Under resting conditions, reduced TRX1 
binds to its inhibiting partner—thioredoxin interacting protein (TXNIP), which is an 
NLRP3 inflammasome activator. The oxidative stress produced by H9c2 EVs 
leads to the dissociation of TRX1 from TXNIP allowing TXNIP to activate NLRP3 
inflammasomes and subsequent IL-1 beta release. 
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Figure 3.8 Differential effects of H9c2_EVs and FL83b_EVs 
on reduced thioredoxin 1 (TRX1) 
(A) Verification of cytoplasmic and nuclear fraction purification by 
western blot of manganese superoxide dismutase (MnSOD) and 
beta actin for cytoplasmic fraction, histone deacetylase 1 (HDAC1) 
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and lamin A/C for nuclear fraction. (B and C) Redox western of 
Trx1 in cytoplasmic fraction (B) and nuclear fraction (C) of 
RAW264.7 treated with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b 
NTEV, or FL83b DOXEV. (D and E) Representative bar graph 
shows the average fold change (n=3) of reduced Trx1 levels in 
cytoplasm (C) and nuclei (D).* p < 0.05 vs vehicle 
Discussion 
DOX is a potent chemotherapeutic agent that is well known to cause 
oxidative stress in normal tissues including the heart and liver. Unfortunately, the 
intercellular communication between injured cells and immune cells in response 
to oxidative stress during DOX treatment is underinvestigated. Here, we 
demonstrate that EVs from heart and liver have different levels of oxidized 
molecules and have different effects on macrophage polarization, which is driven 
by the redox state of TRX1, and ultimately influences NFκB and Nrf-2 activation. 
EVs are released from cells as a compensatory mechanism against 
oxidative stress by removing oxidized molecules to maintain cellular homeostasis 
[179,180]. Previously, we found that circulating EVs released from normal tissue 
targets of DOX are 4HNE-adducted. Moreover, the level of 4HNE adduction in 
EVs correlated with the level of tissue oxidative stress [180]. Our finding in the 
cell culture system was consistent with the in vivo data, in which EVs that are 
released from cardiomyocytes contain higher levels of protein-bound 4HNE than 
hepatocyte-derived EVs. This finding is supported by previous literature reporting 
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that heart tissue has 150 times less catalase, nearly 4 times less superoxide 
dismutase [181], and 27 times less glutathione peroxidase activity [166] than the 
liver. As a result, heart is more susceptible to oxidative stress and DOX toxicity 
than the liver. 
Several lines of evidence show that EVs released during cellular oxidative 
stress can regulate the innate immune response. Oxidized components of EVs 
such as its lipid membrane, proteins, and nucleic acids turn into DAMPs, which 
are recognized by pattern recognition receptors of innate immune cells including 
macrophages [74,75]. Here, we found that EVs from cardiomyocytes induced 
both M1 and M2 macrophage polarization. Macrophages which express both M1 
and M2 phenotypes have been described previously when they have been 
challenged with oxidized phospolipids and were called Mox macrophages. Mox 
macrophages are a redox-regulating phenotype with a high capacity to withstand 
oxidative stress by upregulating anti-oxidant enzymes through Nrf-2 activation 
[182]. However, the N rf-2 com pensation is incom plete so low-level o f 
inflammation still occurs. Mox macrophages contribute to 30% of macrophages 
found in atherosclerotic plaque in mouse model and play a key role in promoting 
chronic low-grade inflammation [183]. Since we observed that EVs from 
cardiomyocytes contains high 4HNE adduction which is an oxidized lipid product, 
and since Nrf-2 activation also occurred, we speculated that the macrophage 
phenotype induced by card iom yocyte  EVs w as M ox. In  th is  system , 
cardiomyocytes released highly oxidized EVs and induced a strong innate 
immune response without any treatment, which is unlikely to occur in vivo. The 
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explanation for this might be that the cells were exposed to 21% O2 in the cell 
culture system, which is much higher than the O2 concentration in tissue (4-14%), 
which caused oxidative stress to the cells at baseline [184]. By contrast, this O2 
concentration issue is negligible for hepatocytes since they contain plenty of 
antioxidant enzymes. When comparing the non-treated and DOX-treated cells, 
DOX promoted EV-mediated immunostimulatory effects in cardiomyocytes but 
not in hepatocytes. This effect is not due to DOX itself because the drug had 
been removed during the washing step. Our in vitro model mimics the clinical 
scenario where cardiotoxicity occurs later, after the cessation of DOX treatment. 
A low-level but persistent inflammation mediated by Mox macrophages induced 
by cardiomycyte-derived EVs could lead to the impairment of cardiac function 
and systemic inflammation that can have the effect on indirect targets of DOX 
such as brain. 
Metabolic reprogramming provides substrates needed for macrophage 
function. In our system, macrophage treatment with cardiomyocyte EVs 
suppressed mitochondrial OXPHOS and promoted glycolysis. Our finding 
corresponds with Mox macrophage metabolism where the cells rely more heavily 
on g lucose m etabolism  and pentose phosphate pathw ay rather than 
mitochondrial respiration. This metabolic shift provides the equivalents required 
for antioxidant synthesis to maintain redox homeostasis [185]. Mitochondrial 
reserve capacity indicates the ability of mitochondria to respond to oxidative 
stress. Hepatocyte EVs promote this capacity and might prevent macrophage 
from ROS-mediated cell damage. 
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TRX1 is a cysteine reductase enzyme in the cytoplasm that maintains a 
reduced state of redox sensitive signaling molecules involved in inflammation. 
Overexpression of TRX1 or administration of recombinant TRX1 is protective 
against severe inflammatory diseases including inflammatory bowel disease 
[186], pancreatitis [61], and sepsis [187]. Here, we demonstrate that TRX1 is a 
key protein that regulates macrophage polarization induced by oxidized EVs. 
Depletion of the reduced form of TRX1 in cytoplasm as a result of cardiomyocyte 
EV treatment might be due to the interaction of TRX1 with oxidized molecules 
that are transferred by EV. As a result, TRX1 deficiency could lead to NFκB 
activation and inflammasome activation. Lower TRX1 levels cause an imbalance 
of cellular redox state, which leads to an adaptive response by enhancing 
antioxidant gene expression through Nrf-2 activation.  
Consequently, NFκB and Nrf-2 activation drive macrophage polarization to 
the intermediate phenotype between M1 and M2. In contrast, hepatocyte EV 
induced higher levels of TRX-1 to counteract oxidatively-modified proteins that 
are transferred to the cells and can maintain cellular redox state. Therefore, 
macrophages treated with hepatocyte EV do not show either M1 or M2 
polarization (Figure 3.9). 
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Figure 3.9 Proposed mechanistic model for the differential 
effects of normal tissue-derived EVs in response to DOX 
treatment on macrophages  
Cardiomyocyte EVs induced M1 and M2 polarization by transferring 
4HNE-adducted proteins to the macrophage, which in turn 
exacerbates oxidative stress in the macrophage by depleting 
reduced cytosolic TRX1. As a result of TRX1 exhaustion, NFκB is 
disinhibited and pro-inflammatory cytokines are produced. Nrf-2 
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activation occurs as a response to oxidative stress due to TRX1 
depletion. DOX aggravates the propagation of oxidative stress by 
cardiomyocyte EVs. In contrast, hepatocyte EVs upregulate 
cytosolic TRX1 leading to the inhibition of both NFκB and Nrf-2 
pathways and make the macrophages remain unactivated. DOX 
potentiates the effect of hepatocyte EVs on TRX1 induction thus 
preventing macrophage polarization. 
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CHAPTER FOUR. CONCLUSION AND FUTURE DIRECTIONS 
Conclusion 
The results presented in this dissertation demonstrate that extracellular 
vesicles (EVs) are early and sensitive biomarkers for DOX-induced 
cardiomyopathy. After DOX treatment the EVs are not only released from 
cardiomyocytes, but also from other direct targets of DOX, such as hepatocytes, 
which have a higher antioxidant capacity and lower sensitivity to DOX toxicity. 
Functional analysis of EVs released from cardiomyocytes and hepatocytes 
reveals that EVs from cardiomyocytes—but not hepatocytes—can propagate 
oxidative stress to macrophages by carrying a high level of 4HNE-adducted 
proteins that disturb the homeostasis of redox regulators and immunomodulators, 
such as thioredoxin (TRX1), leading to macrophage stimulation without any bias 
to M1 or M2 polarization. The ability of hepatocyte EVs to upregulate TRX1 
makes them non-immunostimulatory. The overall results reveal the role of EVs in 
being both biomarkers and mediators of inflammation during DOX treatment.  
DOX, along with at least 50% of chemotherapeutic drugs, generate ROS 
and/or RNS, leading to oxidative stress and normal tissue injuries that limit the 
quality of life for cancer patients. Among the side effects of chemotherapy, 
cardiomyopathy is a life-threatening outcome that is a major concern in the clinic. 
Despite intensive efforts in the discovery of biomarkers for chemotherapy-
induced cardiotoxicity, there is still a lack of sensitive biomarkers that can predict 
toxicity early on before the occurrence of cardiac cell death. Since oxidative 
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stress is an upstream event of cardiotoxicity, resulting from DOX and EVs being 
released in response to oxidative stress, EVs can be a biomarker for oxidative 
stress that is detectable before cardiac cell death. Our data support this 
speculation, since the amount of EVs as well as the oxidative stress markers—
protein-bound 4HNE—increases before cardiac troponin is detectable. Moreover, 
the presence of tissue-specific glycogen phosphorylase (PYGB, PYGM, and 
PYGL) in 4HNE-bound EVs confirms that EVs are released from highly oxidized 
tissues that are direct targets of DOX. Therefore, EV is a biomarker that links 
together oxidative stress markers with tissue-specific markers, making it an ideal 
marker for chemotherapy-induced tissue injury.  
PYGB has been shown to be an early biomarker for cardiac diseases such 
as myocardial ischemia [188,189] and hypertrophic cardiomyopathy [190]. 
Glycogen phosphorylase (GP) is an enzyme responsible for glycogen 
breakdown. Under resting condition, most of the GP is kept dormant (glycogen 
phosphorylase b) by the association with sarcoplasmic reticulum (SR) 
membranes [191]. The proximity of GP and lipid membranes makes it prone to 
4HNE adduction after DOX treatment. 4HNE adduction may prevent the 
dissociation of GP from SR membrane and prevent it from being activated. The 
inhibition of GP function might affect the ability to utilize glucose from glycogen to 
generate ATP and might interfere with the cardiac contraction under stress 
condition, which could be an early sign of chemotherapy-induced 
cardiomyopathy. 
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Different organs have different susceptibility of DOX toxicity. Since EV 
release is a compensatory mechanism to remove toxic oxidized molecules from 
cells under oxidative stress, EVs that are derived from tissues with different 
oxidative stress level might have different functions on the recipient cells. The 
results from chapter 3 demonstrate that cardiomyocytes with a high sensitivity to 
oxidative stress release EVs containing oxidized molecules that activate the pro- 
and anti-inflammatory responses of macrophages. In contrast, hepatocytes with 
a high tolerance to oxidative stress release EVs that do not have immunological 
effects. The function of cardiomyocyte-derived EVs is similar to the effect of 
oxidized LDL that promotes atherosclerosis and persistent inflammation [192]. 
These cytokines can have a local effect on the heart, causing impaired 
myocardial contractions [193], and can be distributed to more distant organs. 
DOX has been shown to induce the pro-inflammatory release of cytokines into 
circulation, including IL-1 beta, TNF alpha, and IL-6 [194]. Prolonged elevation of 
inflammatory cytokines is associated with poor treatment outcome, fatigue, 
anorexia, and recurring tumors in cancer patients [195]. Moreover, our previous 
study found that TNF alpha crosses the blood-brain barrier (BBB) and causes 
neurotoxicity known as chemotherapy-induced cognitive impairment [196]. 
Therefore, inhibiting the effect of oxidized EVs can be a new approach to 
preventing inflammatory responses resulting from DOX. 
In contrast to cardiomyocyte EVs, hepatocyte EVs enhance TRX1 in 
macrophages, suggesting that antioxidant-enriched cells can release EVs to 
protect other cells against oxidative stress. TRX1 has been shown to protect 
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against atherosclerosis and ischemic/reperfusion injury in mice [197,198]. 
Treatment with TRX, including recombinant human thioredoxin, TRX-enriched 
agents, TRX mimetic agents, or TRX inducers has been proven to be effective 
against many inflammatory diseases, including acute pulmonary injury, 
pancreatitis, myocarditis, and chronic obstructive pulmonary disease [199]. 
Based on our results, it is suggested that TRX1 could help to alleviate tissue 
injury resulting from inflammation during DOX treatment.  
Future Directions 
Based on the results in this dissertation, the following experiments may 
warrant future investigation: 
1. Could other types of oxidized lipids and proteins become biomarker 
candidates? 
Since EVs contain different lipid species and different kinds of membrane 
proteins, more comprehensive investigations, such as on lipidomics and oxidized 
lipid labeling methods coupled with mass spectrometry, should be done to obtain 
a complete picture of EV components. 
2. Could EV-associated protein-bound 4HNE and PYGB be used to predict 
long-term cardiotoxicity in cancer patients receiving DOX? 
Because our study relies on mouse model, the results might not represent 
what happens in the clinic. Pre-clinical study in human-derived cardiomyocytes 
should be done to confirm the mouse data. Human-derived cardiomyocytes can 
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be obtained from individual patients experiencing DOX-induced cardiomyopathy 
by differentiation of their induced pluripotent stem cell in vitro [144]. Studying EVs 
from patients-derived cardiomyocytes would provide more precise information 
toward clinical application. To really obtain a new biomarker, clinical investigation 
should be done on cancer patients receiving DOX, and the patients need to be 
followed up long-term.  
3. How long do the EV markers remain in sufficient circulation to be 
detectable after DOX treatment? 
The major hurdle to long-term screening is the half-life of EVs in 
circulation. EVs are more stable than other soluble biomarkers, due to their 
protective lipid bilayer. Previous studies have found that the half-life of 
endogenous EVs (such as human platelet-derived EVs) in circulation is 5.5 hours 
[200]. The clearance is mainly due to the target organ uptake [201]. Therefore, 
the detectability of EVs in circulation depends on the rate of production by the 
tissue of origin and the rate of uptake by the target organ. Further studies should 
be done to evaluate the bioavailability of EVs released from different tissue 
sources in long-term DOX treatment. 
4. What is the function of the tissue-specific subpopulation of EVs on normal 
macrophages? 
 
Since RAW264.7 cells are virus-transformed peritoneal macrophages, 
which are considered leukemic macrophages rather than normal macrophages, 
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they might express different sets of pro- and anti- inflammatory cytokines in 
response to EV treatment comparing to normal macrophages. Therefore, the 
function of EVs in chapter 3 should be confirmed in normal primary macrophages 
such as bone marrow-derived macrophages. Eventhough NR8383 cells are 
considered normal macrophages, they are still derived from alveoli which locates 
away from heart and liver, the two major target organs of DOX. To relate the 
function of EVs on innate immune response that leads to DOX-induced tissue 
inflammation, cardiac resident macrophages, Kupffer cells, or circulatory 
monocytes should be used to confirm the results.  
 
5. What is the function of the tissue-specific subpopulation of EVs in vivo? 
Since all experiments in chapter 3 were done in vitro to study functions of 
EVs on two different macrophage cell lines, the data might not represent what 
happen in vivo. Therefore, in vivo experiments should be done to confirm the in 
vitro study. Such experiments include injection of EVs from non-treated or DOX-
treated cardiomyocytes or hepatocytes into normal mice and measure systemic 
pro- and anti-inflammatory cytokines. Measurement of reduced and oxidized 
forms of TRX1 should be done in bone marrow-derived macrophages isolated 
from those mice to confirm the significance of TRX1 in vivo.  
6. Could oxidized EVs pass the blood-brain barrier and affect the central 
nervous system (CNS), the same way as soluble cytokine? 
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Accumulating evidence has shown that EVs from peripheral blood can 
cross the blood-brain barrier into the CNS [202]. The possible mechanism is 
mediated by adsorptive-mediated transcytosis, where the cationic molecules are 
internalized at the luminal surface of endothelial cells and externalized at the 
opposite surface [202]. Therefore, further study should be done to investigate 
whether EVs can enter the CNS and affect microglia similar to the effect on the 
macrophage. 
7. Could we prevent DOX-induced inflammation by removing oxidized EVs? 
Based on our finding that oxidized EVs act in a similar way to oxidized 
LDL on the macrophage, further study is warranted to find out if the removal of 
EVs (especially 4HNE-adducted EVs) prevents inflammation and systemic 
effects on indirect target organs (similar to the effect of lipid-lowering drugs such 
as statin). However, since the innate immune response is crucial for anti-tumor 
immunity, the prevention of inflammation should be done with caution against 
tumor recurrence.  
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APPENDICES 
APPENDIX A: ACRONYMS 
4HNE 4-hydroxynonenal 
ALT alanine transferase 
CKMM creatine kinase isoenzyme MM 
cTnI cardiac troponin I 
DOX doxorubicin 
DRZ dexrazoxane 
EVs extracellular vesicles 
GP glycogen phosphorylase 
Hp haptoglobin 
MHC-I class I histocompatibility antigen 
MnP Mn(III) meso-tetrakis (N-(n-butoxyethyl)pyridium-2-
yl)porphyrin, MnTnBuOE-2-PyP5+ 
MnSOD manganese superoxide dismutase 
PYGB brain/heart glycogen phosphorylase 
PYGL liver glycogen phosphorylase 
PYGM  muscle glycogen phosphorylase 
RNS reactive nitrogen species 
ROS reactive oxygen species 
SAL saline 
TEM transmission electron microscopy 
TfR1 transferrin receptor 1 
 
124 
 
H9c2 EVs H9c2 cardiomyocyte-derived EVs 
H9c2 NTEV EV from non-treated H9c2 cells 
H9c2 DOXEV EV from DOX-treated H9c2 cells  
FL83b EVs FL83b hepatocyte-derived EVs 
FL83b NTEV EV from non-treated FL83b cells 
FL83b DOXEV EV from DOX-treated FL83b cells 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells 
Nrf-2 nuclear factor (erythroid-derived 2)-like 2 
DAMPs damage-associated molecular patterns 
M1 macrophage pro-inflammatory macrophage 
M2 macrophage anti-inflammatory macrophage 
TNFɑ tumor necrosis factor alpha 
IL-1β interleukin-1 beta 
IL-6 interleukin-6 
IL-10 interleukin-10 
TGFβ transforming growth factor beta 
TRX1 thioredoxin 1 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
tetrazolium 
NO nitric oxide 
IAA iodoacetic acid 
OXPHOS oxidative phosphorylation 
L-NAME N(G)-Nitro-L-arginine methyl ester 
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PRDX-1 peroxiredoxin-1 
HO-1 heme oxygenase-1 
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APPENDIX B. SOLUTION RECIPE 
Cell Culture Media 
 
1. H9c2 growing media Volume Final concentration 
DMEM low glucose 500 ml  
Penicillin/streptomycin 5.725 ml 1% 
FBS 50 ml 10% 
Non-essential amino acids 5 ml 1% 
HEPES 12.5 ml  
Sodium pyruvate 10 ml 1 mM 
Glutamine 5 ml 2 nM 
 
2. FL83b growing media Volume Final concentration 
F12K nutrient mixture  500 ml 
FBS 50 ml 10% 
Penicillin/streptomycin 5.5 ml 1% 
Glutamine 5 ml 1% 
 
3. RAW264.7 growing media Volume Final concentration 
DMEM high glucose 500 ml 
Sodium pyruvate 5 ml 1 mM 
Glutamine 10 ml 4 mM 
FBS 50 ml 10 % 
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Penicillin/streptomycin 5.6 ml 1 % 
 
4. NR8383 growing media Volume Final concentration 
Ham’s F12K medium 500 ml 
Glutamine 5 ml 2 mM 
Sodium bicarbonate 12 ml 1.5 g/L 
Heat inactivated FBS 90 ml 15 % 
Penicillin/streptomycin 6.1 ml 1 % 
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Buffer and Reagents 
 
1. Running buffer (10x)  Volume 
Tris base 12.1 g 
Glycine 38.45 g 
10% SDS 40 ml 
dH2O 400 ml 
 
To make 1x running buffer, dilute 100 ml of 10x running buffer in 900 ml of 
dH2O. 
 
2. Transfer buffer (10x)  Volume 
Glycine 144 g 
Tris base 30 g 
dH2O up to 1 L 
 
To make 1x transfer buffer Volume 
10x transfer buffer 100 ml 
dH2O 700 ml 
methanol 200 ml 
 
3. TBST (Western blot wash buffer) Volume 
3 M Tris-HCL pH 7.5 13.3 ml 
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5 M NaCl 66 ml 
0.5 M EDTA 4 ml 
Tween-20 1 ml 
dH2O up to 2 L 
 
4. G-lysis buffer (6 M)  Volume 
Guanidine.HCl 57.32 g 
EDTA 96.20 mg 
Tris base 788 mg 
Triton X-100 0.5 ml 
dH2O up to 100 ml 
 
Adjust pH to 8.3 with 10 M NaOH 
 
5. G-lysis buffer with 50 mM IAA  Volume 
G-lysis buffer 5 ml 
IAA 46.5 mg 
 
 Prepare solution fresh before protein derivatization 
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6. Hypotonic buffer  Volume 
HEPES 119 mg 
KCL 37.3 mg 
MgCl2 9.5 mg 
EDTA 1.87 mg 
NaF 0.42 mg 
Na3VO4 1.84 mg 
dH2O up to 50 ml 
 
7. Native and non-reducing sample loading buffer (5x) 
1 M Tris.Cl, pH 6.8 3.1 ml 
Glycerol 5 ml 
1% (w/v) bromphenol blue 0.5 ml 
dH2O 1.4 ml 
 
8. Native polyacrylamide separating gel, 15% (2 gels) 
30% polyacrylamide/0.8% bis 8 ml 
1.5 M Tris.Cl, pH 8.8 3.2 ml 
dH2O 3.84 ml 
1.5% ammonium persulfate 0.8 ml 
TEMED 10 μl 
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Pour immediately into the gel frame and allow it to polymerize 
 
9. Native polyacrylamide stacking gel, 6% (2 gels) 
30% polyacrylamide/0.8% bis 1 ml 
0.5 M Tris.Cl, pH 6.8 1 ml 
dH2O 1.85 ml 
1.5% ammonium persulfate 0.6 ml 
TEMED 5 μl 
 
Pour the gel immediately and allow it to polymerize 
 
10. Native running buffer, 10x  Volume 
Tris base 30 g 
Glycine 144 g 
dH2O up to 1 L 
 
Store up to 6 months at room temperature 
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